Emerging Materials and Technologies for Advancing Bioresorbable Surgical Meshes

Behzad Shiroud Heidari, Jagan Mohan Dodda, Labiba K. El-Khordagui, Maria Letizia Focarete, Peter Maroti, Luca Toth, Serafina Pacilio, Salma E. El-Habashy, Joshua Boateng, Ovidio Catanzano, Nitin Sahai, Lingjun Mou, Minghao Zheng

 PII:
 S1742-7061(24)00327-1

 DOI:
 https://doi.org/10.1016/j.actbio.2024.06.012

 Reference:
 ACTBIO 9369



To appear in: Acta Biomaterialia

Received date:5 February 2024Revised date:22 May 2024Accepted date:10 June 2024

Please cite this article as: Behzad Shiroud Heidari, Jagan Mohan Dodda, Labiba K. El-Khordagui, Maria Letizia Focarete, Peter Maroti, Luca Toth, Serafina Pacilio, Salma E. El-Habashy, Joshua Boateng, Ovidio Catanzano, Nitin Sahai, Lingjun Mou, Minghao Zheng, Emerging Materials and Technologies for Advancing Bioresorbable Surgical Meshes, *Acta Biomaterialia* (2024), doi: https://doi.org/10.1016/j.actbio.2024.06.012

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Ltd on behalf of Acta Materialia Inc.

# Emerging Materials and Technologies for Advancing Bioresorbable Surgical Meshes

Behzad Shiroud Heidari<sup>1</sup>, Jagan Mohan Dodda<sup>2\*</sup> Labiba K. El-Khordagui<sup>3</sup>, Maria Letizia Focarete<sup>4</sup>, Peter Maroti<sup>5</sup>, Luca Toth<sup>6</sup>, Serafina Pacilio<sup>4,7</sup>, Salma E. El-Habashy<sup>3</sup>, Joshua Boateng<sup>8</sup>, Ovidio Catanzano<sup>9</sup>, Nitin Sahai<sup>5,10</sup>, Lingjun Mou<sup>11</sup>, Minghao Zheng<sup>1,12</sup>

<sup>1</sup> Centre for Orthopaedic Research, Medical School, The University of Western Australia, Nedlands, WA, Australia

<sup>2</sup> New Technologies – Research Centre (NTC), University of West Bohemia, Univerzitní 8, 301 00 Pilsen, Czech Republic E-mail: jagan@ntc.zcu.cz

<sup>3</sup> Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Egypt

<sup>4</sup> Department of Chemistry "Giacomo Ciamician" and INSTM UdR of Bologna, University of Bologna, Italy.

Health Sciences & Technologies (HST) CIRI, University of Bologna, Via Tolara di Sopra 41/E, 40064 Ozzano Emilia, Italy.

<sup>5</sup> University of Pecs, Medical School, 3D Printing and Visualization Centre, Hungary University of Pecs, Medical Skills Education and Innovation Centre, Hungary

<sup>6</sup> University of Pecs, Medical School, Institute for Translational Medicine, Hungary University of Pecs, Medical School, Department of Neurosurgery, Hungary

<sup>7</sup> Department of Biomedical and Neuromotor Sciences DIBINEM, Alma Mater Studiorum-University of Bologna, Italy.

Applied Biomedical Research Center-CRBA, IRCCS St. Orsola Hospital, Alma Mater Studiorum University of Bologna, Italy.

<sup>8</sup> Faculty of Engineering and Science, University of Greenwich, Medway Campus, UK

<sup>9</sup> Institute for Polymers, Composites and Biomaterials (IPCB-CNR), Via Campi Flegrei 34, 80078 Pozzuoli, NA, Italy.

<sup>10</sup> North Eastern Hill University, Department of Biomedical Engineering, Meghalaya, India

<sup>11</sup> WA Liver and Kidney Transplant Department, Sir Charles Gairdner Hospital, Western Australia, Australia

<sup>12</sup> Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia

#### Abstract

Surgical meshes play a significant role in the treatment of various medical conditions, such as hernias, pelvic floor issues, guided bone regeneration, and wound healing. To date, commercial surgical meshes are typically made of non-absorbable synthetic polymers, notably polypropylene and polytetrafluoroethylene, which are associated with postoperative complications, such as infections. Biological meshes, based on native tissues, have been employed to overcome such complications, though mechanical strength has been a main disadvantage. The right balance in mechanical and biological performances has been achieved by the advent of bioresorbable meshes. Despite improvements, recurrence of clinical complications associated with surgical meshes raises significant concerns regarding the technical adequacy of current materials and designs, pointing to a crucial need for further development. To this end, current research focuses on the design of meshes capable of biominicking native tissue and facilitating the healing process without post-operative complications. Researchers are actively investigating advanced bioresorbable materials, both synthetic and natural biopolymers, while also exploring the performance of therapeutic agents, surface modification methods and advanced manufacturing technologies such as 4D printing. This review seeks to evaluate emerging biomaterials and technologies for enhancing the performance and clinical applicability of the next-generation of surgical meshes.

# **Statement of Significance**

In the ever-transforming landscape of regenerative medicine, the embracement of engineered bioabsorbable surgical meshes stands as a key borderline in addressing persistent challenges and complications associated with existing treatments. The urgency to move beyond conventional non-absorbable meshes, fraught with post-surgery complications, emphasises the necessity of using advanced biomaterials for engineered tissue regeneration.

This review critically examines the growing field of absorbable surgical meshes, considering their potential to transform clinical practice. By strategically marrying mechanical strength with bioresorbable characteristics, these innovative meshes hold the promise of mitigating complications and improving patient outcomes across diverse medical applications. As we navigate the complexities of current medicine, this exploration of engineered absorbable meshes emerges as a light of hope, offering an overall perspective on biomaterials, technologies, and strategies adopted to redefine the future of surgical meshes.

#### **Keywords:**

Surgical meshes, clinical complications, biopolymers, hydrogels, 4D printing, hernia, bone regeneration, wound healing,

JUMARE

### 1. Introduction

Surgical meshes have been used in various applications. The first meshes were clinically used for the treatment of hernia conditions in the 1950s. A tension-free reconstruction of the injured tissue was a significant achievement in hernia surgery using surgical meshes that resulted in better outcomes both in terms of tissue integration and consequent repair [1]. In the 1970s, improvements in the treatment of hernia were reported for the management of pelvic floor dysfunctions (PFDs) such as pelvic organ prolapse (POP) by using surgical meshes [2]. To date, surgical meshes have been manufactured using nonabsorbable materials, especially for hernia and PFDs.

Non-absorbable meshes were developed in the latter half of the 20<sup>th</sup> century to replace metal meshes such as silver wire braided meshes which were abandoned for stiffness and unfavorable outcomes [3]. Non-absorbable meshes possess the required mechanical properties, are easily shaped intraoperatively, and exhibit long-term structural stability [4]. They are intended to remain in the body permanently but may undergo some degradation over time [5]. The most common applications of these types of mesh include breast reconstruction [6], hernia [7] and PFD [8]. Non-absorbable meshes (permanent meshes) are mainly composed of either expanded polytetrafluoroethylene (ePTFE) or polypropylene (PP) [9]. Those meshes show good mechanical properties overall, where tensile strength exceeds the physiological requirements; however, Food and Drug Administration (FDA) reports show that increased inflammation, pain, and infection rates are associated with the application of non-absorbable meshes [9, 10]. For instance, PP mesh has been noted to undergo some degradation *in vivo*, typically due to oxidation. This degradation results in changes in mechanical strength and appearance of surface cracks, which weaken the material further [11]. Additionally, the undesirable oxidation and degradation may cause significant inflammatory cytokines and infiltration of immune cells at the

implantation site [12]. On the other hand, ePTFE is considered a hydrophobic, inert and chemically stable mesh, which allows for resistance to enzymatic attacks during the foreign body response. However, chronic inflammation and remarkable shrinkage are associated with the use of ePTFE mesh [11, 13]. Various approaches have been employed to improve their biocompatibility by either changing the functional physical properties such as porosity to improve cell infiltration or coating with more biocompatible materials that act as barriers to the synthetic mesh material coming into direct contact with the local target tissue [14]. These are designed to reduce local inflammatory/immune responses thereby reducing the chances of complications. Literature information indicated that coating PP meshes with biomaterials such as collagen [15], fibrin [16], and extracellular matrix (ECM) [17] or mesenchymal stem cells [18] their biocompatibility and reduced the inflammatory response. Surface enhanced hydrophilization of PP meshes with titanium treatment (e.g., TiLOOP<sup>®</sup> pfm medical) also reduced chronic pain and immune response [19, 20]. Polymers applied to PP meshes either by simple surface deposition [21, 22] or chemical grafting [23] reduced tissue adhesion and conferred various desirable effects. On the other hand, poor clinical outcomes have been associated with some coated PP meshes such as ETHICON PHYSIOMESH<sup>™</sup> having a laminated layer of poliglecaprone 25 and C-Qur (Atrium) mesh coated with omega-3 fatty acid because of a higher hernia recurrence and reoperation rate compared to similar products. Indeed, the mesh antiadhesive properties of C-Qur (Atrium) decline over time leading to dense abdominal adhesions necessitating mesh explantation [24-26].

Despite relevant biocompatibility enhancement, challenges in nano-absorbable surgical meshes have not been completely resolved as they are still associated with a risk of postoperative infection, pain, fistulation and need for explantation in contaminated settings [1, 27, 28]. This led

to the evolving of biological mesh products in the first decade of the century, e.g. Strattice<sup>TM</sup> RTM, Permacol<sup>™</sup>, AlloDerm<sup>TM</sup>, etc., with expected reduced rates of infection and other shortcomings associated with permanent meshes [29].

Biological meshes/patches were introduced to reduce the risk of infections associated with synthetic non-absorbable meshes [29]. These are composed of an ECM that is derived from collagen-rich tissues [30]. Biological implants become vascularized over time, resulting in the deposition of host collagen that provides integrity as the strength of the mesh dissipates over time [31]. However, undesirable host reaction to the biologic mesh is a significant disadvantage [10, 29]. A higher rate of reactions is attributed to the biologic properties of the mesh, such as the source animal's DNA, stimulating an immunologic response [32]. In a study reporting adverse effects associated with various surgical meshes for hernia repair, biologic meshes (from human or animal collagen) elicited higher foreign body reactions compared to synthetic and composite meshes [10]. In another report, both Strattice<sup>TM</sup> (porcine, non-cross-linked tissue matrix) and Tutomesh® (bovine, collagen I membrane were associated with an acute, short-term inflammatory response as a macrophage-foreign-body reaction around mesh filaments [29]. Another disadvantage of biological meshes is their high cost [10, 30]. The evidence base supporting the use of biological mesh is currently too limited to support routine clinical use, restricting it to mostly niche applications. Current evidence increasingly supports reconsidering synthetic mesh as the prosthesis of choice for elective open ventral hernia repair even in contaminated cases [33].

The key takeaway from the pre-clinical and clinical studies focusing on non-absorbable and biological surgical meshes is that not every innovation transfers to improved patient care or better clinical outcomes. The limitations and failures of the developments highlighted the

importance of proper materials selection and the need of appropriate surgical techniques. These setbacks will also guide the development of future generations of prostheses with greater efficacy. Nevertheless, such failures may guide the development of future generations of prostheses with greater efficacy. Assuming appropriate surgical technique and mesh placement, flaws have generally involved long-term interactions of the prosthesis system (base / surface modification materials / fixation tool), its architecture and manufacturing method, and the host tissues and organs [13]. Improvements require collaborative efforts between surgeons, material scientists and biomedical engineers to optimize the mesh composition and structural design. Moreover, the evidence base needs to be improved in future studies via a standard approach for the description of mesh type and exact placement, and consistent monitoring of the intervention regarding recurrence rate, infection, and seroma to enable reliable assessment and reproducibility of clinical outcomes. The evidence base may be also improved by testing the efficacy of the mesh in randomized trials and the inclusion of more high-risk patient cases to establish the limits of indication [34]. From a regulatory perspective, sufficiently rigorous requirements to demonstrate the safety of the prosthesis must be satisfied to gain clearance.

In the quest for more reliable implants for use inside the peritoneal cavity, bioresorbable meshes evolved as a slowly resorbable synthetic mesh, combining the benefits of both synthetic (no early degradation after implantation) and biological meshes (the "remodeling" aspects and better tolerance in case of contamination) [35]. Bioresorbable surgical meshes are temporary implants that can be slowly degraded or replaced by healing tissue and integrated within the body's innate repair mechanisms. The term "bioresorbable" is reserved for those polymeric systems that can degrade into low molecular weight compounds that are involved normally in metabolic pathways, or which can be, at least, eliminated from the body through natural

pathways [36]. Bioresorption reflects the total elimination of the initial foreign material and of the degradation by-products (low molecular weight compounds) with no residual material remaining [37]. Consequently, this avoids the need for further surgical procedures to remove the implants or scaffolds [38, 39]. Bioresorbable meshes maintain mechanical strength for a predetermined period. These implants will gradually resorb, allowing regeneration of connective tissue. In this way, this new generation of materials is different from the available quickly absorbing polyglactin mesh (Vicryl mesh; Johnson & Johnson) [35].

Over the last decade, many different bioresorbable meshes have been designed and developed using natural, synthetic and composite biomaterials. There is an increasing trend in tissue engineering to use naturally occurring macromolecules as a starting material to prepare scaffolds for tissue remodeling such as hydrogels and meshes, since such materials are well tolerated and have an inherent bioactivity including promotion of cell proliferation and adhesion [40]. This is the result of the intrinsic properties of biodegradable hydrogels, the most significant being degradation, bioadhesion bioactivity, transport, controlled release of drug and bioactive molecules, and mechanical properties [41]. In particular, the biodegradation of hydrogels is based on a number of mechanisms, such as hydrolysis, proteolysis, or environmental triggers. The desired hydrogel bioresorbability can be achieved by designing the material with a controlled number of degradable crosslinks in the polymer network. This feature of hydrogels allows researchers to design anti-adhesive or drug-eluting mesh-hydrogel composites to prevent some serious complications in clinical studies, especially for hernia repair. Furthermore, hydrogel-mesh composites have been recently advanced by adopting 4D biofabrication methods, which employ programmable shape-transformations of preliminary 3D constructs, using smart

hydrogels that respond to external stimuli such as pH, temperature, and magnetic fields to achieve desired morphology [42].

Current research efforts focus on providing potential solutions that range from the formulation of multi-functional biomaterials to new biofabrication techniques that could ameliorate existent shortcomings in clinical use of surgical meshes. The aim of this review is to provide an overview of emerging biomaterials and technologies for enhancing the preclinical and clinical performance of advanced surgical meshes.

## 2. Ideal surgical mesh and regulations

Although the "ideal" mesh has not been developed yet, the continuous developments in the field and the appearance of advanced materials have created the basis for designing the optimal mesh. An early study highlighted that surgical meshes must be inert, resistant to infections and other side-effects, adequate mechanical stability and non-carcinogenic [43]. In the past two decades, other aspects have occurred, like the need for cost-effectiveness, shape memory effect, flexibility and easy handling [44]. In addition, the use of lightweight materials is encouraged [44, 45]. **Table 1** describes the properties of an ideal surgical mesh according to its application.

| Properties               | Description  |  |  |  |  |
|--------------------------|--|--|--|--|--|
| 2                        | The mesh material should be biologically compatible to           |  |  |  |  |
| $D_{1}^{1} = 120$        | minimize the risk of adverse reactions or inflammation. In       |  |  |  |  |
| Biocompany [45, 40]      | addition, the mesh should be easily sterilized to prevent        |  |  |  |  |
|                          | postoperative infections   |  |  |  |  |
|                          | Sufficient tensile strength is crucial to withstand the forces   |  |  |  |  |
| Tensile properties and   | exerted on the mesh and provide structural support. Furthermore, |  |  |  |  |
| stiffening behavior [47] | the mesh should have some degree of compliance to adapt to the   |  |  |  |  |
|                          | surrounding tissue and prevent stiffness or discomfort.          |  |  |  |  |

Table 1. Properties of an ideal surgical mesh.

| Pore size and structure [48]                                     | Optimal pore size and geometry promote tissue ingrowth and vascularization while preventing complications such as adhesions.   |  |  |  |
|--|--|--|--|--|
| Surface bioactivity and<br>anti-adhesion<br>(if applicable) [46] | Coatings with bioactive substances can enhance tissue<br>integration, reduce inflammation, and prevent infection.<br>Coatings that resist tissue adhesion can reduce the risk of<br>postoperative complications, such as adhesions between organs. |  |  |  |
| Biodegradability [48]  | In some applications, a biodegradable mesh that degrades over<br>time may be preferred, especially if long-term structural support<br>is not necessary.  |  |  |  |
| Postoperative visualization [46]                                 | The mesh should be visible on imaging studies (such as X-rays<br>magnetic resonance imaging (MRI) or computer tomography<br>(CT) scans) to enable postoperative assessment.  |  |  |  |
| Ease of handling and placement [44, 46]                          | The mesh should be easy to handle and manipulate during surgery, conforming to the anatomical site.  |  |  |  |

As the field of implantable meshes is rapidly developing, which is fundamental for contemporary personalized and advanced medical solutions, there is an international regulation for these solutions based on the United States (US) FDA and European Union (EU) Medical Device Regulation (MDR), which strictly regulate and control the new device applications taking safety as primarily aim during implementation. In 2017, the FDA Center for Devices and Radiological Health (CDRH) published its top ten regulatory science priorities for medical devices, including using "big data" for regulatory decision-making, modernized biocompatibility evaluation, computational modelling technologies, precision medicine and biomarkers [49, 50]. As per the code of the US Food and Drug Administration (FDA), surgical mesh is identified as "a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where

weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair and acetabular and cement restrictor mesh used during orthopedic surgery" [51].

The EU MDR came into force in May 2017, which applies to implantable and long-term surgically invasive devices (> 30 days). These are primarily implants in the orthopedic, dental, ophthalmic, and cardiovascular fields and soft tissue implants such as those used in plastic surgery. Breast implants and surgical meshes are classified as class III devices under Rule 8. The US FDA approved the first urogynecological mesh only 20 years ago [8]. Due to safety concerns, the FDA withdrew some vaginal mesh products for stress urinary incontinence (SUI) and POP from 2011 to 2019 [8]. In addition, some countries such as New Zealand, the United Kingdom and Australia discontinued the application of pelvic floor dysfunction PFD meshes. These withdrawals were in response to various complications following mesh implantation including infection, pain, discomfort and erosion into the vagina and in some cases, some patients had to undergo follow-up surgery [52]. 3D-printed and 3D bioprinted meshes have gained attention in the last decade due to their better surgical results with the latter approach able to design and print different types of matrices based on biocompatible polymers and biomaterials as well as the ability to embed bioactives such as cells and proteins [1, 53]. For example, Dewey and co-workers reported that incorporating 3D-printed bone mesh improved the behavior of mineralized collagen scaffolds in terms of their mechanical and osteogenic performance [54]. The scaffolds were designed for the reconstruction of craniofacial bone defects caused by different factors including cancer treatments, congenital abnormalities and trauma. Ren et al. [55] fabricated a resorbable mesh with antibacterial properties and controlled degradation rates via 3D printing of polycaprolactone/polyethylene glycol-based matrices, to overcome problems associated with the traditional polypropylene-based meshes. In 2017, the US FDA issued guidelines that included information on materials, design, printing methods, post-processing, and validation [1].

# 3. Biomaterials for bioresorbable meshes

Bioresorbable polymers can be classified into naturally occurring and synthetic materials. Natural materials derive from animals or plants, including the decellularized extracellular matrix (dECM) obtained from allografts and xenografts, and cover a wide range of organic materials such as polysaccharides [hyaluronic acid (HA), chondroitin sulphate, heparin, dextran, alginate, cellulose, chitin, and chitosan-(CS)], and polypeptides (collagen, gelatin, silk fibroin, albumin, elastin, and keratin) [56, 57]. Natural biomaterials are highly biocompatible and have a favorable pro-remodeling host immune response [58]. However, they exhibit great variability owing to their biological source, and are often not suitable for load-bearing applications due to limited physical and mechanical stability [59]. These drawbacks can be compensated by synthetic polymers, which are materials of great interest in the medical field [14]. Synthetic biomaterials offer several advantages over traditional natural materials, including the possibility of being precisely and consistently manufactured with minimal variability. Due to the controlled physical and mechanical properties that can be easily tuned, however, biocompatibility is a major concern since cells may have difficulty attaching and growing, and consequently might elicit a proinflammatory response in the host [60]. An increasing number of studies have therefore been carried out to exploit the advantages of both classes of biomaterials, either by improving the mechanical properties and shape stability of natural biomaterials or by developing processes to modify the surface and bulk properties of synthetic biomaterials to enhance their biocompatibility [61, 62].

In 1959, Francis Usher introduced the initial synthetic mesh composed of PP for hernia repair applications. Subsequently, there was a burgeoning progress of mesh technology, which led to extensive biophysical and clinical investigations aiming at discovering the perfect mesh. Through the utilization of synthetic, natural, and composite biomaterials, many different resorbable meshes have been developed [63, 64]. The majority of bioresorbable meshes consist of biodegradable synthetic polymers, such as polyglycolic acid (PGA), polylactic acid (PLA), and poly(lactic-co-glycolic) (PLGA; a copolymer of PLA and PGA). It is important to emphasize that these absorbable materials undergo degradation, and their degradation rate must align with the duration required for tissue regeneration, since after degradation, the tissue support is diminished, therefore the application must be carefully considered to avoid complications or lesion recurrence [65-67]. Despite their initial popularity, PGA meshes are no longer employed due to their rapid degradation. As a result, there has been a notable emergence of biosynthetic polymers that show complete biodegradation over a mid- to long-term period for surgical applications.

The main aim of developing biomaterials is to diminish the foreign body reaction within the host and facilitate tissue regeneration [68]. PLGA was employed in the production of several commercial meshes, such as POLYGLACTIN 910 (Vicryl<sup>TM</sup>, Ethicon) [13]. Despite the better degradation rate, PLA-based meshes still present complications such as foreign body granuloma and giant cell formation [69]. Biodegradable Gore<sup>®</sup> BIO-A mesh was developed by copolymerization of 67% of PGA and 33% of trimethylene carbonate (TMC), and in preclinical and clinical studies showed promising results in mechanical endurance and tissue integration. Another fully absorbable material in the field is TGR<sup>TM</sup> (Matrix Surgical Mesh; Novus Scientific Ltd., Singapore), which comprises two types of synthetic fibers (co-polymer glycolide-lactide TMC/lactide and TMC) with a multifilament structure, with satisfactory preclinical and limited clinical results [68, 70, 71].

Various natural bioresorbable materials are used in surgical mesh development. Biosynthetic resorbable meshes encompass materials based on silk fibroin (SF), gelatin, collagen, polyhydroxyalkanoates, and plant fiber-based materials. Notably, insect-based protein products such as SF extracted from silkworms, specifically Bombyx mori, have garnered attention due to their exceptional mechanical properties and resorption time of up to 2 years, positioning them as potential competitors to biological matrices [72, 73]. Combination approaches involving electrospun SF and other materials with high biocompatibility, such as poly(3-hydroxybutyrate-co-3-hydroxyvalerate), have been explored to produce hybrid scaffolds that demonstrate high efficiency and biocompatibility according to the *in vitro* and *in vivo* studies [74, 75]. The increased resistance to surgical site infections associated with bacterial poly(4hydroxybutyrate) (P4HB) surgical meshes has made this material of extreme interest in hernia repair procedures. Bioresorbable meshes based on P4HB (Phasix<sup>TM</sup>, BD Bard, Rhode Island, USA) were engineered to maintain structural integrity long enough to allow for tissue ingrowth but also completely degrading to avoid the complications associated with permanent mesh materials.

Unique material properties tailored for specific biomedical applications can be obtained by modulating biomaterial chemistry and synthesizing composites made of a combination of natural and synthetic materials [76-78]. The benefits of this approach include shorter operative time, decreased technical difficulty in tissue repair, and the ability to mimic the *in vivo* microenvironment better to stimulate normal tissue or organ development [79]. Gao and co-workers have provided an interesting example of how the combination of natural and synthetic

polymers with a specific design can improve the properties of a biomaterial [80]. The authors proposed a design called hydrogel-mesh composites (HMCs) which broadens the function of surgical meshes by adding one important property: strong tissue adhesion (**Figure 1**). They demonstrated that HMCs form strong and swell-resistant adhesion with various tissues under physiological environments, as well as on tissues under high pressure or great tension. Finding a balance between the fabrication method and biomaterial selection, to match the properties between the scaffold and the target tissue, will be key to the field of tissue engineering in the future.



**Figure 1.** Design and potential advantage of a HMC. (**A**) Schematic of the HMC. In the HMC, the hydrogel and the surgical mesh (polyethylene terephthalate) form topological entanglement. The hydrogel has long polymer chains of two types: Type I polymers (poly(N-isopropylacrylamide)) form a covalent network, and type II polymers (CS) carry functional groups (amino groups) for adhesion to a tissue. When an HMC contacts a tissue, the hydrogel and tissue adhere through complementary functional groups. Wound closure using three materials: (**B**) HMC, (**C**) suture, and (**D**) tissue-adhesive hydrogel. Reproduced with permission from Ref [80]. Copyright 2021 National Academy of Sciences.

Resorbable polymer meshes are widely available on the market, but several preclinical *in vitro* and *in vivo* experiments had to precede commercialization. The experimental studies aiming to analyze degradation profiles of polymeric meshes in preclinical settings guarantee the safety and improve the understanding of the degradation phenomenon of meshes under *in vivo* conditions leading to better clinical application [81-83]. Several preclinical studies on different animal models (rabbit, sheep, rats, minipigs, pigs, vervets) were performed on commercially available synthetic resorbable meshes like GORE BIO-A<sup>®</sup> and Phasix<sup>TM</sup> and showed promising results as sites for cell proliferation [35, 84].

# 4. Surface modification in anti-adhesive meshes

Tissue adhesion and fibrosis can be a major complication during wound healing via surgical meshes; hence, the anti-adhesion functionality is a primary challenge in mesh preparation, particularly for PP meshes, which are widely used by clinicians. For abdominal wall reconstruction, anti-adhesive properties prevent the formation of adhesions between the mesh and abdominal organs, decreasing the risk of bowel obstructions, chronic pain, and other complications. Efforts to address this issue and develop antiadhesive properties in mesh materials continue to be a central focus in research and development. The main concept behind antiadhesion mesh development is to effectively restrict fibrosis, recognizing its close association with adhesion formation in hernia regions [85].

Research studies have demonstrated that materials such as CS, HA, and absorbable oxidized regenerated cellulose (ORC) possess antiadhesion properties. As a result, many antiadhesion treatments are applied to meshes by using those antiadhesion agents [86-88]. Among the antiadhesion products certified by the FDA, Interceed<sup>®</sup> produced by J&J, is prepared from ORC [89]. In 2018, Lai *et al.* [87] modified bacterial cellulose using TEMPO (2,2,6,6-

tetramethylpyperidine-1-oxyl) to enhance its properties while retaining its favorable tensile properties and elastic modulus. Their findings demonstrated that modified cellulose exhibited preferential adsorption of bovine serum albumin, resulting in improved secretion of type I collagen, inhibition of fibroblast proliferation, and subsequent reduction of adhesion [87]. Alongside the application of antiadhesion agents, the antiadhesion membrane serves as a physical barrier, effectively isolating the surgical site from adjacent organs or tissues. *In-vivo* biocompatibility evaluation of polyethylene glycol (PEG) hydrogels hybridized with HA was performed after intramuscular and subcutaneous administration to a mice model. Histologic and hematological parameters analyzed at varying time intervals (7, 14, and 21 days) including the hematopoietic system showed promising outcomes on HA release during hydrogel degradation [90]. The study used the pig model, and conventional laparotomy pelvic surgery was performed after histopathological evaluation and concluded that resorbable HA reduces laparotomy pelvic surgery-induced adhesion [91].

Most of the commercial surgical meshes are inert without groups to react with the grafted compounds, particularly for hernia repair applications. Hence, plasma treatment, using oxygen or argon gas, is employed to activate the inert surface of the mesh for functionalization [92, 93]. For instance, oxygen plasma activation was employed to treat a PP mesh, followed by the grafting of polyvinyl alcohol (PVA) onto the mesh with the assistance of hydrogen peroxide [94]. Subsequently, the PP-g-PVA mesh was implanted into mice [94]. Remarkably, adhesion was only observed in small corners, constituting less than 2% of the total area, while the remaining region exhibited a remarkably smooth surface [94]. Most recently, an antiadhesive PP mesh was developed with PVA hydrogel and liposomes (LPS) drug delivery system (**Figure 2A**) [95]. First, the PVA hydrogel coating was prepared by a freezing-thawing process; then, rapamycin

(RPM)-loaded LPS were immobilized in the PVA hydrogel. Findings showed that the hydrogel coating was stable on PP mesh at 37 °C for 30 days. The optimal antiadhesive composite mesh showed a slighter inflammation response and remarkably looser fibrous tissue surrounding the PP filaments as compared to the native PP through *in vivo* experiments [95].

Electrospun nanofibrous membranes possess the ability to mimic the ECM structure and effectively modulate cellular behavior. Unlike knitted structures, these membranes offer distinct structural characteristics that can cater to specific performance needs on each side [96]. By incorporating a nanofiber-based layer, physical isolation can be achieved between organs or tissues and the mesh. This isolation prevents fibroblast adhesion and proliferation between these entities, consequently mitigating the risks of bridging and organ adhesion [85]. PLGA/CS (PLGA and CS) nanofibers were electrospun on PP mesh and then the antiadhesion effects of PLGA/CS nanofibers were evaluated in pre-clinical studies [88]. The peritoneal adhesion score of the PP/PLGA-CS30 mesh (containing 30% chitosan) was 59% lower than that of the pure PP mesh [88]. Aydemir Sezer et al. [97] developed an antiadhesion PP hernia mesh by incorporating micrometer-sized particles of absorbable ORC and PCL using the electrospinning technique. PP/PCL-ORC20 mesh (PCL/ORC coated PP mesh with 20% ORC) showed best tensile properties (ultimate strength: ~30 MPa, modulus: ~42 MPa, elongation at break: ~112%) among the samples, while the inclusion of PCL facilitated controlled degradation, reducing acidity, and improving biocompatibility. Animal experiments demonstrated that the antiadhesion performance depended on the concentration of ORC, suggesting that a combination of ORC with a more efficient antiadhesion polymer could enhance the effectiveness of the composite mesh [97]. Recently, nanofiber membranes (NFM) composed of PLGA and PCL showed a good physical barrier in vitro [98, 99]. An adhesive composite hernia mesh was prepared by

integration of PP substrate with an alginate hydrogel (AH) layer containing a NFM barrier (**Figure 2B**) [98]. *In vivo* experiments on rabbits indicated that incorporating AH-assistant NFM into the PP prostheses significantly reduced visceral adhesion and enhanced mesh integration into nearby tissues from the abdominal wall [98].



**Figure 2.** Antiadhesion surgical meshes. (**A**) The schematic illustration of the drug-loaded hydrophilic hydrogel coating RPM@LPS/PVA. Reproduced with permission from Ref [95]. Copyright 2023, with permission from Elsevier. (**B**) Schematic illustration showing the strategy to endow PP mesh with a barrier composed of a NFM and AH layers for preventing adhesion formation in abdominal wall hernia repairs in rabbit model. Reproduced with permission from Ref [98]. Copyright 2022, with permission from Elsevier.

In clinical practice, it is more often a combination of the physical antiadhesive layer and the regulation of biochemical agents that can ultimately boost the antiadhesion effect. The

strategy of combining hydrogel and dopamine to functionalize the mesh has been considered by researchers in order to remodel the ECM via the hydrogel and overcome the problem of poor adhesion of hydrogel to tissue by dopamine or L-3,4-dihydroxyphenylalanine (L-DOPA; a chemical precursor to dopamine) [100, 101]. For instance, dual-functional layer membranes/meshes have been developed to optimize the performance of each function, such as a bifunctional two-sided PP mesh, in which one side was coated with PCL nanofibers with antiadhesion and antibacterial function; and on the other side, the PCL nanofibers were treated with a mussel-derived L-DOPA binder [100].

In addition to problems with adhesion when implanted *in vivo*, synthetic meshes will typically result in a foreign body response by the body's defence system, with various consequences including scar tissue formation, degradation of local tissue with resultant inflammation, chronic pain and discomfort at the site of application [102]. This is particularly common with hernia meshes, the majority of which are made from PP. Therefore several efforts have been made to functionalize the surface of synthetic meshes (surface coating) using various approaches including nanoparticle-based matrices [103]; biocompatible polymers such as polyester, collagen, PLGA, polyvinyl pyrrolidone, PVA, CS and cellulose-based polymers [104-106], as well as using bioinspired materials naturally present in the body such as platelet-rich plasma (PRP) [107]. Furthermore, these surface coatings also serve as vehicles for local delivery of therapeutic agents such as growth factors, [1] antibiotics [108] and antimicrobial agents [109].

In a recent study, Yu *et al.* [110] employed a warp-knitting approach to fabricate hernia meshes made from PP and coated them with CS and alginate solutions to impart hydrophilic properties to the meshes. The resulting surface-coated meshes were characterized for surface

morphology (SEM and AFM) and wettability (contact angle goigniometry), cell attachment (ectomesenchymal stem cells derived from male Sprague-Dawley rats), cell viability and proliferation of the ectomesenchymal stem cells. Their results showed that the PP mesh coated with CS and alginate showed improved cytocompatibility and reduced side effects which facilitated cell attachment and proliferation for rapid healing compared to the plain meshes.

In a similar study, Seraphim *et al.* [111] designed bioinspired coatings to bioactivate PP meshes. The coatings were based on methacryloyl gelatin and methacryloyl mucin hydrogels with or without PRP supplementation. The successful coating was confirmed by FTIR spectroscopy, homogeneity of the coating and stability in a simulated biological matrix by SEM and micro-computed tomography CT and biological cell assays showed that the hydrogel coatings could stimulate and modulate fibroblast activity on the meshes.

### 5. Drug-eluting bioresorbable meshes

Resorbable hydrogels are engineered to deliver the drug locally for extended periods and are capable of being HMCs resulting in significantly better and more effective meshes [80]. Advanced surgical meshes with drugs loaded into the mesh structure have attracted much attention in the field of regenerative medicine. The incorporation of antibacterial drug/coating is underway to address the current clinical issue of inflammation and infection [9]. Antibiotics have been highly employed for bacteria-specific treatment, including rifampicin, fluoroquinolones (e.g. ofloxacin, ciprofloxacin, levofloxacin), metronidazole, gentamicin, etc [112]. The application of carboxymethylcellulose (CMC) gel loaded with chlorhexidine was developed to study the antibacterial effect at the defect area *in vivo*. This showed that antibacterial gel-coated PP meshes can inhibit bacterial adhesion to the mesh surface and have no impact on wound

repair [113]. Reinbold et al. [114] utilized rifampicin in hernia management by fabricating rifampicin-loaded PLGA microspheres used for coating the surgical mesh. The microspherescoated meshes showed a controlled release profile of rifampicin over 60 days and an antibacterial activity over 30 days. The antibacterial effect of an ofloxacin/PCL-coated PP mesh was studied for hernia repair applications [115]. The mesh successfully achieved a controlled antibiotic release profile with no mechanical failure (i.e. burst) over 4 days. From the antibacterial analysis of E. coli, the inhibition zone diameter of 39 mm indicates a potent antibacterial activity [115]. In another work, minocycline-loaded CS nanoparticles were incorporated into a collagen/CS membrane. In vitro drug release tests showed that the antibiotic release was sustained for up to 7 days, with an initial burst release [116]. The woven cotton fabric was modified with gentamicin (Gem) via the enamine bonds and combined with a commercial PP mesh to serve as a two-layer composite mesh for abdominal wall defect repair (Figure 3A) [117]. The obtained mesh showed antibacterial properties against E. coli and S. aureus with a bactericidal rate of over 99.99%. The two-layer composite mesh indicated great biocompatibility and satisfactory anti-infective properties in abdominal wall defect repair in a rat model [117]. Loading growth factors and other biological molecules can improve the hosting and colonization of stem cells on hernia meshes and inhibit inflammatory reactions to enhance wound healing [1, 9, 118].



**Figure 3.** (A) Schematic illustration of the preparation of antibacterial cotton fabric (Cotton-Acac-Gem) (i) and combination with PP tissue mesh for abdominal wall defect repair (ii). t-BAA: tert-Butyl acetoacetate; Cotton-Acac: cotton transestericifacted with acetoacetyl groups; Gem: gentamicin; CAG: Cotton-Acac-Gem. Reproduced with permission from Ref [117]. Copyright 2020 American Chemical Society. (B) Zn-loaded PCL coaxial fibers and their antibacterial mechanisms, which are releasing  $Zn^{2+}$  ions and photocatalytic reactive oxygen species (ROS) generation. Reproduced with permission from Ref [119]. Copyright 2018, with permission from Elsevier.

Natural-based antimicrobial molecules have also been used in advanced hernia mesh to achieve a better integration of the mesh with the surrounding tissue and with less cytotoxic side effects [1]. For example, Mancuso *et al.* prepared an antibacterial PCL fibrous mesh for soft tissue regeneration by layer-by-layer deposition of Manuka honey, which did not change the physicochemical feature of the implant, while the layer-by-layer functionalization showed a concentration-dependent antimicrobial activity against *S. aureus, E. coli* and *P. aeruginosa* with good *in vitro* cytocompatibility for fibroblast and endothelial cells [120].

Metal and metal oxide nanoparticles (MNPs) can also be used as therapeutic agents and loaded into surgical meshes with/without hydrogel incorporation. Muwaffak *et al.* showed the antibacterial properties of MNPs-loaded PCL mesh by studying the efficacy of silver-loaded (Ag-loaded), zinc-loaded (Zn-loaded) and copper-loaded (Cu-loaded) meshes. They reported higher activity of Ag and Cu against *S. aureus* [121]. Recently, a non-electrospun bioactive 3D nanofibrous hybrid micromesh consisting of PLA nanofibrous microspheres loaded with didecyldimethylammonium bromide-modified zinc oxide nanoparticles (D-nZnO) demonstrated significant antibacterial, regenerative, and hemostatic functionalities through *in vitro* wound healing assays [122].

In another work, an antibacterial wound mat was fabricated by coaxial electrospinning to prepare PCL (core) loaded with Zn nanoparticles (shell) (**Figure 3B**) [119]. Antibacterial tests were carried out against *S. aureus* and *E. coli*, indicating that mats possess two main antibacterial mechanisms; release of  $Zn^{2+}$  ions and generation of photocatalytic ROS which together allowed inhibition of planktonic and bacterial biofilm growth and improvement of the mats' antibacterial properties [119]. Besides Zn nanoparticles, the positive antimicrobial effects of silver nanoparticles (Ag-NP) have long been known and used in clinical chemistry. Sobczak–Kupiec *et* 

*al.* attached Ag-NP by microwave irradiation to polymeric matrix poly(acrylic acid) and gelatinbased polymer/hydroxyapatite (HAP) composite to assess the possible decomposition changes of the material due to silver supplementation, and found greater degradation behavior for samples containing 4% to 5% HAP in artificial saliva and simulating body fluid, influencing the antimicrobial functionality and release profile of the nanoparticles [123]. **Figure 4** illustrates the roles of different biomaterials, nanoparticles, and therapeutic agents in the structure of a bioresorbable mesh used for wound healing on a pre-clinical mouse model.



**Figure 4.** Schematic representation depicting the roles of different biomaterials, nanoparticles, and therapeutic agents in the structure of a bioresorbable mesh used for wound healing on a preclinical mouse model.

# 6. Advanced technologies in bioresorbable meshes

Surgical meshes, like PP mesh, are traditionally produced by fiber extrusion, melt-spinning, and wet-spinning; however, several different technologies have been investigated to fabricate bioresorbable hernia meshes in the last decade. Electrospinning is one of the emerging fabrication technologies for bioresorbable surgical meshes [124]. Electrospinning involves applying an electric field to create material fibers in nanoscale diameter. This method allows for

the production of meshes with a high surface-to-volume ratio with the ability to incorporate drugs or bioactive agents into the fibers [125, 126]. Recently, an electrospun composite ibuprofen-loaded (PEG/PCL) NFM has been fabricated aiming to be used in hernia repair and to prevent abdominal adhesions. In the *in vivo* animal study, the optimal membrane (PCL/25PEG-6%) created a barrier between the abdominal wall and surrounding tissues, exhibited normal wound healing without interrupting mass transfer and showed a sustainable drug profile release ( $\approx$ 80%) within 14 days [127].

3D printing, also known as additive manufacturing, is another emerging technique that offers unique advantages in terms of mesh properties and customization. This technology allows the creation of complex mesh structures with precise control over the composition, pore size and geometric shapes of meshes. In addition, biological compounds such as ECM proteins, cells and drugs can be used in 3D printing to create innovative devices and living biologically active tissue constructs [128]. For instance, drug distribution in the mesh can be achieved by incorporating drug-loaded filaments or microspheres into the mesh structure in predetermined locations. This concept, known as bioprinting, has great potential for regenerative hernia repairs [129]. For instance, PCL meshes were 3D-printed with two different pore sizes containing sodium alginateencapsulated Gem [130]. The antibacterial activity of these devices was assessed in vitro. The drug-loaded meshes showed good antibacterial activity in vitro against E. coli, as well as mild inflammation and early tissue repair of the abdominal wall in a rat model. However, adhesions to the mesh limited its intraperitoneal applicability [130]. Bioabsorbable PLA containing Gem was 3D-printed to assess antibacterial characteristics against S. aureus and E. coli. The results showed the feasibility of incorporating drugs into the 3D printed meshes, without losing the antibacterial effectiveness [131]. 3D printing via single or multi-head extrusion was employed to

fabricate layer-by-layer (LbL) meshes based on (TEMPO)-oxidized cellulose nanofibrils (TOCNF) and CS (Figure 5) [53]. 3D-printed nanocellulose mesh was immersed in the CS polymer solution to obtain CS-sorbed nanocellulose mesh. The non-cytotoxicity toward human monocyte/macrophages and controllable shrinkage upon solvent exchange make the cellular meshes appropriate for use as biomedical implants [53]. Recently, an innovative bioinspired micromesh-integrated **3D**-printed hydrogel construct developed was as an antibacterial/regenerative bilayer scaffold for treating diabetic wounds [132]. A HA/CS ink was used to fabricate a bilayer construct composed of an upper dense hydrogel layer on top of a lower regenerative/antibacterial layer with hierarchical porosity achieved by incorporating PLA nanofibrous micromeshes embedded with nano D-nZnO, developed earlier[122]. The scaffold afforded 95% wound-closure, infection control, regulation of three healing-associated biomarkers and skin regeneration in 14 days in vitro.

Melt electrowriting (MEW) and 4D printing are two advanced biofabrication technologies that have the potential to revolutionize surgical mesh production by introducing innovative designs, adaptability and controlled properties. MEW has been recently used to gain a precise and continuous deposition of microfibrous structures. MEW is typically based on applying a voltage to generate a stable molten fluid jet and drawing out a single fiber onto a pre-determined path [96]. In surgical mesh production, MEW offers two main advantages, extrusion of ultrafine fibers and fabrication of complex mesh designs with specific pore sizes, orientations, and patterns, which can optimize mechanical performance and match patient-specific anatomical requirements [133]. Examples of MEW mesh with different architectures are presented in **Figure 5** [134, 135]. Recently, Ren *et al.* [136] fabricated degradable PCL/PEG composite meshes using MEW. Two PCL/PEG mesh groups: 90:10 and 75:25 (PCL: PEG, wt%) were fabricated and

characterized for their degradation rate and mechanical properties, with PCL meshes used as a control. The antibacterial properties of the meshes were elicited by coating them with azithromycin. *In vitro* studies indicated that the PCL/PEG meshes with antibiotic coating will be effective after about 2 weeks of drug release and the mesh can support human mesenchymal stem cell attachment and proliferation [136].





advanced technologies Figure 5. Examples of in bioresorbable meshes. 3D printing/Bioprinting: Schematics of the three approaches used to develop 3D printed mesh structures from nanocellulose (TOCNF) and chitosan, including mixing the components before printing; the mixture was evaluated by in situ imaging of TOCNF and TOCNF-chitosan mixture under rheology tests at low (0.15 s<sup>-1</sup>) and high (700 s<sup>-1</sup>) shear rates; Double printheads (PH1 containing TOCNF and PH2 containing chitosan) were used to deposit multilayers; 3D printed nanocellulose mesh was immersed in the chitosan polymer solution to obtain chitosan-sorbed nanocellulose mesh. Reproduced with permission from Ref [53]. Copyright 2021 The Authors. MEW (melt electrowritten): A schematic of a stable molten fluid jet that is direct-written onto a substrate onto a pre-determined path; SEM images of the 3 MEW meshes with different patterns and printing path amplitudes. Scale bars are 1 mm. Reproduced with permission from Ref [134, 135]. Copyright 2019 The Authors. Copyright 2020 The Authors. 4D printing: illustration of 4D printing for fabrication of patterned alginate/methylcellulose (Alg/MC) hydrogels and their 3D deformations on immersion in 0.1 M CaCl<sub>2</sub> solution. Reproduced with permission from Ref [137]. Copyright 2021 The Author(s).

The next generation of additive manufacturing is so-called 4D-printing, which adds an extra dimension of time-dependent shape transformation to 3D-printed geometries. This emerging technology seeks to resolve the limitations of 3D-printed structures to mimic the dynamics of living tissues by introducing "time" as a new parameter [138]. In 4D-printing, the smart biomaterials respond to physicochemical or biochemical stimuli (e.g., temperature, pressure, presence of molecules, pH), resulting in shape changes or functional transformations over time [139]. Hence, 4D-printing offers the potential to create meshes with adaptive properties and enhanced functionality in surgical mesh applications. Stimuli-responsive biomaterials could be used to prepare pioneer meshes with the ability to progressively adapt and respond to changes in the host-tissue environment, enhancing tissue generation and implant compliance [129]. Printable Alg/MC hydrogels were 4D-printed into the 2D meshes, which were encoded with anisotropic stiffness and swelling properties by tailoring the network density gradients vertically to the orientation of the patterned strips (**Figure 5**) [137]. The dynamic deformations of the printed Alg/MC hydrogels into helix structures or rolling structures, depending on the orientation of the patterned strips, occurred after immersion in a calcium

chloride solution (0.1 M) [137]. Lanzalaco *et al.* [140] investigated the 4D behavior of a substrate of knitted fibers of isotactic PP (iPP) mesh with a coating of thermosensitive poly(N-isopropylacrylamide-coN,N'-methylene bis(acrylamide) (PNIPAAm-co-MBA) hydrogel when subjected to cycles of increase/decrease temperature and by considering different mesh configurations and humidity conditions. The presence of the iPP mesh and the distribution of the gel surrounding the PP threads affected both the PNIPAAM gel expansion/contraction as well as the time of folding/unfolding response. In addition, PP-g-PNIPAAm meshes indicated an improvement in the bursting strength of 16% with respect to the uncoated mesh, suggesting a very strong and adaptable system after implantation [140].

# 7. Clinical applications of bioresorbable meshes

Surgical meshes were first and widely introduced for hernia repair applications in clinical practice however, as technology improved, other clinical fields got involved including cardiovascular interventions, gynecology, dentistry, dermatology and orthopedics. Resorbable polymer mesh applications have the great benefit of tissue support for the critical time period when it is needed or even stimulate tissue regeneration and proliferation. In the end, they get completely broken down and dissolved, avoiding long-term complications, such as foreign body reactions, scarring or occlusion. The resorption time of bioresorbable meshes varies based on the type of polymer used and the construct design and porosity. With known degradation mechanisms, the chemistry, molar mass, and crystallinity of degradable polymers can be tuned to realize the combination of mechanical properties and degradation rates required for diverse clinical needs. Clinically, the most frequently used bioresorbable polymer materials are: PLLA bioresorbable by hydrolysis and complete metabolism of lactic acid at physiologic temperature with an average 60% reduction by 18 months; polydioxanone (PDO) bioresorption varies from a

few weeks to 12 months; PCL undergoes degradation over 24 months; porcine collagen enzymatic degradation ranges between 2 weeks to 3-4 months; PGA can be resorbed within a month and P4HB over 12 months [141, 142].

The time typically required for supported healing depends on the clinical scenario and the physicochemical and structural characteristics of the prosthesis including porosity and topographical cues. For instance, a hernia mesh needs to remain in place until tissue integration is complete which usually takes around 2-3 weeks after surgery, but the mesh can take longer to completely dissolve [143]. In wound healing applications, an electrospun hybrid-scale fiber matrix (Restrata®) composed of two synthetic biocompatible and biodegradable polymers polyglactin 910 and PDO and possessing a structure of varying fiber diameters with high porosity was approved for the healing of different types of wounds. The FDA-approved fibrous matrix undergoes resorption at a rate ideally matching the process of new tissue formation and acute wound healing over the course of 2-3 weeks, on average [144, 145]. For the treatment of chronic wounds of varying etiologies in patients with different demographics, the matrixsupported treatment was required for 12-21 weeks for chronic wounds including diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) [146-148], eight weeks for post-Mohs wounds [149], eleven weeks for hematomas and complex pressure ulcers [150, 151] and 23 weeks for augmented flap reconstruction of complex pressure ulcers [152]. Table 2 shows the properties of the clinically used bioresorbable surgical meshes, patches and plates along with their clinical outcomes.

**Table 2.** The characteristics of the clinically used bioresorbable surgical meshes, patches and plates along with their clinical outcomes.

| Name of the base |            | **        | Resorption | Clinical applications, in |
|------------------|------------|-----------|------------|---------------------------|
| biomaterial      | Brand name | Pore size | time       | vivo studies              |

| PGA N  | leoveil <sup>™</sup> Sheet  | NA<br>(nonwoven)                              | 3 weeks                                      | Reducing pancreas-related  |
|--|---|---|--|--|
|  |   | (nonwoven)                                    |  | minimally invasive surgery   |
|  |   |   |  | for gastric cancer [153]   |
| DI A 2   | D printed mach  | 2 mm  | 1.2 years                                    | Diocompatible mash with  |
| FLA 5.   | D-printed mesh  | 5 11111                                       | 1-2 years                                    | afficient electicity and tensile   |
|  |   |   |  | strength for hernia repair   |
|  |   |   |  | [154]  |
|  |   |   |  |  |
| G  | Guidor <sup>®</sup>   | combination                                   | 1 year                                       | GBR in dentistry improves  |
|  |   | of layers with                                |  | soft tissue mass in ridge  |
|  |   | different pore                                |  | preservation [155]   |
|  |   | sizes   |  |  |
| PDO D  | JuraSorb™   | >1mm  | 6-8 months                                   | Successful soft tissue   |
|  |   |   |  | reinforcement e.g. in  |
|  |   |   |  | revisional breast surgery  |
| DOL  |   | 500   |  |  |
| PCL T  | ink Nasal Mesh;   | 500 µm  | 20 months                                    | Corrective rhinoplasty, with   |
|  | &R Biofab Co.,  |   |  | good effectivity and no side   |
|  | Ltd, Sineung,   | . 0   |  | effects [157]  |
|  | COLVEL ACTIN  | 2 mm  | 3 months                                     | Biological mash is superior  |
|  | 0LTOLACTIN  | 2 11111                                       | 5 months                                     | in the surgical treatment of   |
| ,  | i (vieryi )   |   |  | infected incisional hernia   |
|  |   | *   |  | with a similar recurrence rate   |
|  |   |   |  | [1,50]   |
| 67% PGA + 33% G  |   |   |  | 158  |
| 0,70 1011 1 2270 0   | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.  | 1-3 mm  | 6 months                                     | [158]<br>Low recurrence and no   |
| TMC  | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &  | 1-3 mm  | 6 months                                     | Low recurrence and no<br>complications in the  |
| TMC L  | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,  | 1-3 mm  | 6 months                                     | Low recurrence and no<br>complications in the<br>treatment of large hiatal   |
| TMC L  | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)  | 1-3 mm  | 6 months                                     | Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal   |
| TMC L  | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)  | 1-3 mm  | 6 months                                     | Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and   |
| TMC L  | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)  | 1-3 mm  | 6 months                                     | Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia  |
| TMC L  | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)  | 1-3 mm  | 6 months                                     | Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]  |
| TMC L<br>glycolide + lactide + T   | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)  | 1-3 mm<br>1-1.5 mm                            | 6 months<br>26 months                        | Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]<br>Safe and effective in inguinal  |
| TMC L<br>glycolide + lactide + T<br>TMC (I   | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)<br>CIGR <sup>TM*</sup><br>Novus Scientific   | 1-3 mm<br>1-1.5 mm                            | 6 months 26 months                           | Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]<br>Safe and effective in inguinal<br>hernia repair [70]  |
| TMC L<br>glycolide + lactide + T<br>TMC (I<br>L  | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)<br>CIGR <sup>TM*</sup><br>Novus Scientific<br>.td., Singapore)   | 1-3 mm<br>1-1.5 mm                            | 6 months 26 months                           | Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]<br>Safe and effective in inguinal<br>hernia repair [70]  |
| TMC L<br>glycolide + lactide + T<br>TMC (I<br>P4HB P                                   | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)<br>CIGR <sup>™</sup> *<br>Novus Scientific<br>.td., Singapore)<br>'hasix <sup>™</sup>  | 1-3 mm<br>1-1.5 mm<br>0.5 – 1 mm              | 6 months 26 months 12-18 months              | [158]Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]Safe and effective in inguinal<br>hernia repair [70]Efficient and safe in case of<br>limited biased |
| TMC L<br>glycolide + lactide + T<br>TMC (1<br>P4HB P                                   | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)<br>TIGR <sup>™*</sup><br>Novus Scientific<br>.td., Singapore)<br>'hasix <sup>™</sup>   | 1-3 mm<br>1-1.5 mm<br>0.5 – 1 mm              | 6 months 26 months 12-18 months              | [158]Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]Safe and effective in inguinal<br>hernia repair [70]Efficient and safe in case of<br>complicated hiatal hernia and<br>uentral hernia in hernia   |
| TMC L<br>glycolide + lactide + T<br>TMC (I<br>P4HB P                                   | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)<br>TIGR <sup>™</sup> *<br>Novus Scientific<br>_td., Singapore)<br><sup>t</sup> hasix <sup>™</sup>  | 1-3 mm<br>1-1.5 mm<br>0.5 – 1 mm              | 6 months 26 months 12-18 months              | [158]Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]Safe and effective in inguinal<br>hernia repair [70]Efficient and safe in case of<br>complicated hiatal hernia and<br>ventral hernia repair in high-<br>rick patients [161, 162]   |
| TMC L<br>glycolide + lactide + T<br>TMC (1<br>P4HB P                                   | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)<br>CIGR <sup>TM*</sup><br>Novus Scientific<br>Ltd., Singapore)<br>Phasix <sup>TM</sup>   | 1-3 mm<br>1-1.5 mm<br>0.5 – 1 mm              | 6 months 26 months 12-18 months              | [158]Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]Safe and effective in inguinal<br>hernia repair [70]Efficient and safe in case of<br>complicated hiatal hernia and<br>ventral hernia repair in high-<br>risk patients [161, 162]Safe and effective in prime and<br>sofe and effective in prime and   |
| TMC L<br>glycolide + lactide + T<br>TMC (I<br>P4HB P<br>bovine collagen + C<br>PI GA P | Gore <sup>®</sup> BIO-A <sup>®</sup> (W.<br>Gore &<br>Associates Inc.,<br>JSA)<br>TIGR <sup>TM*</sup><br>Novus Scientific<br>.td., Singapore)<br><sup>1</sup> hasix <sup>TM</sup><br>DviTex <sup>®</sup> (TELA<br>Bio, Inc. Melvern | 1-3 mm<br>1-1.5 mm<br>0.5 – 1 mm<br>50-300 μm | 6 months 26 months 12-18 months 10-12 months | [158]Low recurrence and no<br>complications in the<br>treatment of large hiatal<br>hernia, large paraesophageal<br>hiatal hernia, and<br>contaminated ventral hernia<br>[28, 159, 160]Safe and effective in inguinal<br>hernia repair [70]Efficient and safe in case of<br>complicated hiatal hernia and<br>ventral hernia repair in high-<br>risk patients [161, 162]Safe and effective in primary<br>or recurrent hiatal hernia  |

| polyester + collagen | Parietex <sup>TM*</sup>                   | 1.5-1.8 mm   | >18 months   | Promising results were              |
|----------------------|---|--------------|--------------|-------------------------------------|
| + PEG + glycerol     |   |              |              | shown in different types of         |
|                      |   |              |              | hernia, but safety concerns         |
|                      |   |              |              | were raised [164_165]               |
| DTEE   DCA/TMC       | Core <sup>®</sup> Supacor <sup>®</sup> (W | 1.2 mm       | 67 months    | Successful in ventral and           |
| PTFE + PGA/TMC       | Gore Synecor (w.                          | 1-3 mm       | o-/ months   | Successiul in ventral and           |
|                      | L. Gore &                                 |              |              | inguinal hernia repair (based       |
|                      | Associates Inc.,                          |              |              | on recurrence rate,                 |
|                      | USA)                                      |              |              | complications and patients          |
|                      |   |              |              | feedback) [166, 167]                |
| Synthetic PEG        | CoSeal <sup>®*</sup>                      | NA           | 5-7 days     | Early studies on                    |
|                      | (Angiotech                                |              |              | myomectomy patients                 |
|                      | Pharmaceuticals.                          |              |              | showed good results, but            |
|                      | Inc. Canada)                              |              |              | safety concerns were raised         |
|                      | men, cumulu)                              |              | X            |                                     |
| PI GA + fibroblasts  | Dermagraft <sup>®</sup>                   | 0 5-1 mm     | 20-30 days   | In combination with standard        |
| I LOIX + Horoolasts  | (Organoganasis                            | 0.5 1 1111   | 20 50 days   | trastmant proved to be              |
|                      | (Organogenesis,                           |              |              | deathent proved to be               |
|                      | Canton, USA)                              |              |              | significantly better in chronic     |
|                      |   |              |              | foot ulcer treatment [169,          |
|                      |   |              |              | 170]                                |
| Collagen             | CelGro™                                   | 0.5-1 mm     | 4 months     | Successful GBR in dentistry         |
|                      | (Orthocell Ltd.,                          |              |              | [171]                               |
|                      | Murdoch,                                  |              |              |                                     |
|                      | Australia)                                |              |              |                                     |
| PLLA + HA            | Osteotrans MX <sup>®</sup>                | 100 - 500 µm | 3-5.5 years  | Maxillofacial bone                  |
|                      | (TEIJIN Medical                           | ·            |              | replacement [172]                   |
|                      | Corp., Osaka.                             |              |              |                                     |
|                      | Japan)                                    |              |              |                                     |
|                      | RapidSorb <sup>®</sup>                    |              | 12-18 months | Plate systems were used in          |
|                      | 85:15                                     |              |              | maxillofacial surgery. Both         |
|                      | (DePuy Synthes                            |              |              | of the systems are effective        |
| ΡΙΙΔ/ΡGΔ             | CMF West                                  |              |              | and have low complication           |
| hioracorhable        | Chaster USA)                              | 50.200 um    |              | rate however Lectosorb <sup>®</sup> |
|                      | Luture 1 <sup>®</sup>                     | 50-500 μm    |              | Tate, nowever, Lactosofb            |
| osteosynthetic plate |   |              |              | was innked to a nigher              |
|                      | 82:18                                     |              |              | incidence of complications          |
|                      | (Lorenz Surgical,                         |              |              | vs. RapidSorb <sup>®</sup> [173]    |
|                      | Jacksonville, USA)                        |              |              |                                     |

\* FDA recall

\*\* The pore sizes are based on the factory and publication data, however, might vary depending on the application of the mesh.

### 7.1. Hernia repair applications

Hernia occurs when a part of an organ moves through a weakened muscle into a different body segment, which could be an inherited or acquired condition, and the classification is based on the localization of the disorder. In hiatus hernia (HH), a part of the stomach is moved to the mediastinum via the weakened diaphragm. Protrusion of intestinal or fat tissue due to abdominal wall weakness results in different types of abdominal hernia including inguinal hernia when intestinal tissue is squeezed through the lower abdominal wall [174]. The standard treatment of hernia is surgical, with mesh reinforcement to release the pressure on the tissues and decrease the complication rate [175].

OviTex<sup>®</sup>, an FDA-approved ovine polymer-reinforced bioscaffold with PP or PGA, was used in an open complex abdominal wall reconstruction (CAWR) for fifty-five patients in the Netherlands [176]. None of the patients with a surgical site infection that made direct contact with the mesh needed mesh explantation for persistent infection involving the mesh. Hence, the reinforced mesh can withstand infectious complications and provide acceptable mid-term recurrence rates. However, longer follow-up data from prospective studies are required to determine further risk of hernia recurrence in that study [176]. In another study, a PP-reinforced tissue matrix (OviTex<sup>®</sup>) was successfully tested on 25 primary or recurrent HH repair patients. The results indicated successful relief of symptoms, no perioperative complications or recurrence of HH during the relatively short follow-up period [163]. The operation technique of HH highly depends on the size of the lesion. For instance, treatment of a large HH (>5 cm) with a bioresorbable mesh (Gore Bio A<sup>®</sup>) made of PGA/TMC with an estimated resorption time of 6 months was found superior regarding recurrence (in the first 2 years) vs. non-mesh treatment [177]. Although a similar recurrence rate was noted in five years, an earlier failure rate was

observed in the non-mesh group at 12 months. Low recurrence rate and complication-free recovery were demonstrated in a small study treating paraesophageal HH with Gore Bio-A<sup>®</sup> [159]. Furthermore, Bio-A<sup>®</sup> proved to be effective in long-term recurrence in the treatment of contaminated ventral hernia, where an increased risk for post-operative infection is present [160]. TIGR<sup>TM</sup> is a synthetic surgical mesh, made of two different synthetic resorbable fibers containing a distinct proportion of glycolide, lactide and TMC, resulting in a longer absorption time [70]. Although the initial results for uncomplicated inguinal repair were encouraging, in the case of complicated hernias, the recurrence and complication rates were high, leading to FDA recall. In 2018, Renard *et al.* compared the use of resorbable synthetic (Vicryl<sup>®</sup>) and biological (Strattice<sup>®</sup>) meshes to treat infected incisional hernia and found Strattice<sup>®</sup> superior to Vicryl in terms of early and late postoperative infections [158].

Recently, a slowly resorbable biosynthetic Phasix<sup>™</sup> mesh (**Figure 6A** and **B**) made of P4HB scaffold with PGA and hydrogel barrier was tested in the repair of large and complicated HH with either laparoscopic or robotic surgery technique resulted in promising clinical outcomes including absence of migration, stenosis, recurrence or dysphagia in 30 patients [178-180]. In 2018, Renard *et al.* compared the use of resorbable synthetic (Vicryl<sup>®</sup>) and biological meshes to treat infected incisional hernia and found Strattice<sup>™</sup> superior to Vicryl in terms of early and late postoperative infections [158]. Later, slowly resorbable biosynthetic meshes made of P4HB (Phasix<sup>™</sup>) with a slower breakdown profile and capable of inducing cell proliferation proved to be effective tools to treat infected incisional hernias avoiding chronic infection or mesh removal within one-year follow-up in 29 patients [181]. Furthermore, this mesh was shown to be safe and effective in high-risk incisional hernia patients during a five-year follow-up [162].

As a next generation of the meshes, a hybrid PTFE and PGA/TMC scaffold (Synecor<sup>TM</sup>), selected to enhance mechanical strength and stimulate tissue proliferation and vascularization, respectively, was tested on 35 ventral hernia patients [166]. During the two-year follow-up, no recurrency occurred and the infection rate was in line with previous data. In addition, patients reported satisfaction with significant improvement, especially regarding self-esteem, and relief of pain and discomfort with only one patient needing reoperation. Based on a recent trial, involving 157 patients, Synecor<sup>™</sup> is safe and effective in inguinal hernia repair considering the recurrence and complication rates together with patient-reported pain [167]. Parietex<sup>™</sup> composite ventral patch is made of polyester with absorbable collagen, PEG, and glycerol. The patch has a fixation system composed of four monofilament polyester flaps and two removable handles complete the device. This fixation system and the three-dimensional reinforcement material are assembled with absorbable PGLA expanders as shown in Figure 6C-E [182]. The Parietex<sup>TM</sup> composite ventral patch has been successfully used with a low recurrence rate in different types of hernia in 48 patients and effectivity could be further induced by implementing Parietex<sup>TM</sup> composite mesh overlaid by an aponeurotic graft in large incisional hernia repairs [164, 165]. A recent meta-analysis involving the comparison of synthetic, biologic, or bioabsorbable use of meshes for complicated ventral hernia cases reported similar results. Recurrence rate and infection were lowest in the case of the bioresorbable meshes, with similar seroma rates compared to the other two meshes implying the effectiveness of bioresorbable meshes [28]. Furthermore, Phasix<sup>TM</sup> has demonstrated to be able to maintain 80% and 18% greater strength than the native abdominal wall at 8 and 72 weeks post-implantation, respectively, despite significant biopolymer degradation [183]. However, the ability of P4HB to promote the expression of the antimicrobial peptide (AMP) cathelicidin LL-37 in macrophages

[184] makes this type of surgical mesh capable of decreasing the incidence of post-operative surgical site infection when compared with other surgical meshes [185, 186]. Although clinical trials are limited, the application of this material in ventral hernia repair has shown good outcomes with an effective reduction of hernia recurrence rate [187-189]. Quality of life improvements were noted with no recurrences after two years [190] despite a recurrence rate of 9% for inguinal hernia repair observed at 18 months post-implantation [161]. A more recent five-year hernia repair follow-up of Phasix<sup>™</sup> mesh in high-risk patients demonstrated a recurrence rate of 15.9 %, low pain scores, and no mesh-related complications or reoperations for chronic pain, confirming the potential of this biomaterial to prepare meshes for hernia repair [189]. Despite the promising results, Parietex<sup>™</sup> was withdrawn in 2018 from FDA approval due to safety concerns in the case of parastomal hernia repair.

Journal



**Figure 6.** (A) PHASIX Mesh comprised of a fully resorbable, P4HB monofilament knitted into a flat sheet configuration. Reproduced with permission from Ref [179]. Copyright 2013 Corey R. Deeken and Brent D. Matthews. (B) SEM of Phasix<sup>TM</sup> ST Mesh (40× magnification; scale bar =  $200 \,\mu$ m). Phasix<sup>TM</sup> ST Mesh is comprised of fully resorbable P4HB fibers co-knitted with polyglycolic acid (PGA) and coated with a resorbable hydrogel layer on the visceral side of the mesh. The hydrogel layer is comprised of sodium HA, CMC, and PEG. Reproduced with permission from Ref [180]. Copyright 2022 Becton Dickinson (BD). (C) Peritoneal surface of Parietex<sup>TM</sup> showing two positioning loops attached to four flaps composed of polyester monofilament. (D) Parietex<sup>TM</sup>, subcutaneous side. (E) Parietex<sup>TM</sup>, peritoneal side. Reproduced with permission from Ref [182]. Copyright 20115, with permission from Elsevier. (F) Polyglactin mesh. (G) Dermagraft as received from a pack, (H) dermal fibroblasts cultured on polyglactin mesh. Reproduced with permission from Ref [191]. Copyright 2010 John Wiley & Sons, Inc.

### 7.2. Gynecological applications

Following abdominal or pelvic surgery the appearance of pelvic adhesion is a very frequent complication occurring in around 95% of patients following pelvic surgery and resulting in chronic pain, altered organ motility or even bowel obstruction [168]. The application of surgical mesh in gynecological applications, especially transvaginal mesh for POP and SUI, has been associated with safety concerns for women [192]. The transvaginal meshes were reclassified from moderate-risk class II devices to high-risk class III devices in 2016, meaning the 510(k) process can no longer be used for mesh products to gain market access. That reclassification resulted in a sharp decrease in using transvaginal mesh for POP repair surgery [193]. The observation and assessment of the surgeries confirmed the high level of risks with respect to the benefits; therefore, the FDA ordered mesh manufacturers to stop selling and distributing surgical meshes intended for transvaginal repair of anterior prolapse (cystocele) on April 16, 2019 [194]. In addition, the Therapeutic Goods Administration (TGA) cancelled the approval of urogynecological meshes for POP repair surgery (through the vagina) and SUI repair surgery (single incision mini-slings) in November 2017 [195].

Several attempts were made to develop anti-adhesive membranes, such as CoSeal<sup>®</sup> which is a resorbable hydrogel made of two different synthetic PEGs. Crosslinking of the two polymers upon ejection from a syringe results in the formation of a barrier capable of inhibiting adhesion in the acute and subacute periods, getting completely resorbed within a month [168].

CoSeal<sup>®</sup> was successfully tested in preclinical models and a randomized controlled clinical trial on myomectomy patients and proved to be safe and effective by significantly decreasing adhesion both in high and lower-risk patients without any notable complication or adverse event [168]. Regardless of the positive early clinical data, FDA approval was withdrawn due to the

potentially incomplete dissolution of PEG and its inappropriate effect on tissue integration led to safety concerns [196].

Different types of implants and meshes have been also tested during sarcocolpopexy surgery, the treatment of for example vaginal prolapse, to decrease the operation-caused complications such as recurrence or infection [197]. A partially resorbable graft composed of PP and polyglecaprone showed mechanically good results without significant complications. However, the composite PP graft was withdrawn shortly after its introduction to clinical practice, leading to the use of non-resorbable polyvinylidene fluoride in sarcocolpopexy. The polymer showed similar results as far as anatomical success, patient satisfaction or complication rate are concerned [197].

# 7.3. Wound healing

Acute skin lesions such as burns or chronic lesions such as ulcers are common disorders, severely affecting the quality of life. Even with modern absorbent wound dressing materials (e.g. alginate), the definite treatment and success rate is still limited, especially in the case of infected ulcers (e.g. in diabetic patients). This may lead to systemic complications and even life-threatening septic states. Several preclinical trials aimed to develop partly or completely resorbable wound healing polymer-based hydrogels with promising results and the development of next-generation drugs or stimulating factor eluting meshes [198, 199]. The most frequently used polymers are HA, collagen, and PLGA exhibiting a controlled degradation profile synergizing with epithelialization (skin healing) and PEG which induces proliferation and collagen precipitation. Other polymers include PCL with high structural properties but limited capacity against microorganisms. Polymers lacking antimicrobial activity are therefore frequently combined with Ag-NP to induce matrix proliferation in an antimicrobial environment or even sericin derived from a moth or spider combined with collagen to achieve improved

resorption and antimicrobial effects in preclinical trials for burn injuries [199, 200]. Several commercially available and approved polymer appliances have proved to be effective in wound healing, such as resorbable HA matrix (Hyalomatrix<sup>®</sup>) successfully used in burn injuries. Furthermore, a knitted PLGA mesh, as typically shown in **Figure 6F**, was cultured with human neonatal fibroblasts leading to the development of one commercial product of cryopreserved Dermagraft<sup>®</sup> (Advanced Tissue Sciences) (**Figure 6G**) [191]. The knitted PLGA meshes support homogenous cell distribution and withstand the cell contractile force (**Figure 6H**) [191]. Dermagraft<sup>®</sup> was successfully applied extensively on chronic ulcers with good clinical healing results without complications [1, 169, 199, 201].

Generally, acute wounds tend to heal within 3 weeks while chronic wounds tend to persist for a minimum of 3 months from the time of injury. A matrix with optimal handling properties and a rate of resorption ideally matched to the process of new tissue formation and wound healing [201]. Once applied to a wound, the matrix supports cellular infiltration, new tissue formation, and wound healing while progressively resorbing into the tissue over the course of 2 weeks, on average. [202].

# 7.4. Dentistry applications

In dental care, there are several conditions where GBR is indicated, in order to provide the necessary amount and quality of bone tissue for implantology [203, 204]. Membranes in the GBR procedure serve as a cell-occlusive barrier, which prevents the regeneration of epithelial and connective tissues in the wound, maintaining a space for the migration of pluripotent and osteogenic cells [203, 205, 206]. Two main types of resorbable polymer meshes and membranes are employed in dentistry: the group of collagens as natural polymers, and the group of synthetic polyesters. **Figure 7A** shows the application of GBR in surgical procedures. Following a

treatment plan for extraction, the defect site is debrided, and the bone is perforated (**Figure 7A(i)**) by the surgeon prior to implantation of the bone graft and membrane. Dental bone graft is placed in the void socket to promote bone growth (**Figure 7A(ii)**) while the barrier membrane is implanted sub gingivally over the alveolar ridge to protect the bone growth within the socket and prevent gingival ingrowth (**Figure 7A(iii**)). Finally, the tissue closure is performed when applicable (**Figure 7A(iv**)) [207].

In the 2010s, Jung et. al examined the clinical outcome of 265 dental implants, involving 72 patients. In the study, the researchers aimed to compare the practical efficacy of resorbable and non-resorbable membranes. All the patients received deproteinized bovine bone mineral (DBBM) in combination either with a collagen or an expanded PTFE (e-PTFE) membrane and confirmed that both resorbable and non-resorbable membrane systems are safe, reliable, predictable and have a long survival rate (91.9% and 92.5%, respectively) during the median follow up-time of 12.5 years [208].

The effectiveness of collagen membranes was enhanced when used in combination with a bone graft [209]. A promising clinical outcome (9 months postoperative) was observed for using bone grafting material (BioOss) and a membrane (AlloDerm<sup>®</sup> GBR) to treat a class I ridge defect. The patient experienced significant hard and soft tissue growth [209]. In another study, CelGro<sup>TM</sup> (Orthocell Ltd.), a type I collagen bilayer membrane, was employed in a clinical study for a total of 16 dental implants, which were placed in 10 participants receiving GBR. The results showed that Celgro<sup>TM</sup> restores bone defects with no complications or adverse events [171]. A recent study compared collagen-based membranes with synthetic PLA resorbable membranes during the dental implantation process and showed no clinically significant change in facial bone thickness reduction implying that synthetic and resorbable polymer membranes can be equally

used to support aesthetic implantology [210]. Furthermore, in a small study, PLA-based membrane proved to be effective in ridge preservation for soft tissue regeneration [155]. Interestingly, ridge augmentation treatment extended with platelet-rich factor or dehydrated human amnion-chorion membranes did not have a significantly different clinically visible effect on vital bone formation or augmentation compared to traditional collagen membranes. However, it caused a slight pain reduction in patients who had undergone lateral ridge augmentation, followed by mandibular ramus block harvesting [211-213].

# 7.5. Maxillofacial surgery

Facial bones could be damaged by injuries, trauma, tumor, and infection and can also be affected by congenital anomalies [214]. Results regarding the reconstruction methods of facial bones have a widely and well described in the literature, and it must be noted, that surgical techniques and materials strongly depend on the actual deformity, origin of bone defect and characteristics of patients [214].

In 2005, an early study investigated the use of resorbable membranes in the treatment of unilateral cleft palate in 15 participants divided into three different treatment groups: autogenous iliac bone graft (AEG) alone; ePTFE; (Gore-Tex<sup>TM</sup>) membrane implanted alone; while the third group was treated with a resorbable PLA/PGA membrane, combined with ABG [215]. GBR has been found successful both with membranes and with standalone ABG, however, the authors reported significantly better results with combined techniques following radiological evaluation [215]. Subsequently, 3D-printed PCL meshes were successfully implemented for rhinoplasty patients supporting cartilage repair and airway opening during healing time, without considerable side effects [157].

Biodegradable polymers can also be mixed with HAP. The use of a composite product (Osteotrans MX<sup>®</sup>) composed of un-sintered PLLA/HAP can support fracture stabilization and reossification with minimal complications (**Figure 7B-D**) [172]. Because they are osteoconductive and biodegradable, the u-HA/PLLA nanocomposites can be used for complete replacement by bony tissue in addition to the advantages of early functional improvements [216]. The same research group investigated the complications related to PLLA/PGA copolymer plate and mesh systems used in maxillofacial surgery. In total, 87 patients were involved in the retrospective study which concluded that PLLA/PGA is a useful material for maxillofacial osteosynthesis, with a good healing process and rapid resorption however, it must be noted that plate thickness was associated with the risk of exposed plates as a complication, therefore right diameter selection is essential [173]. Among 147 patients with midfacial trauma or dentofacial deformity as complication plate exposure was 7.4%, infection was 2.4% and plate breakage was 0.7%, respectively, when PLLA/PGA meshes and plates were used for reconstruction. Furthermore, also interestingly, the authors concluded that female sex and the greater number of plates are risk factors for perioperative complications [217].

Not only synthetic but natural polymer-based membranes can be used in the treatment of intra-bony defects in the maxillofacial region [218]. With the participation of 18 patients, resorbable collagen membranes have been used to treat mandibular defects, based on HAP grafting, supported with the addition of PRP and significant bone density growth was observed on the radiography images in the 1<sup>st</sup> and 6<sup>th</sup> month after treatment [218]. Interestingly, a previous research work concluded that using collagen membrane is disadvantageous, compared to the addition of  $\beta$ -tricalcium phosphate because of the decreased bone regeneration, which is in agreement with the findings related to GBR in dental applications, in comparison with titanium

implants [219, 220]. To overcome these challenges, a new technique and material was introduced in 2017. The method used a resorbable polymeric thermo-reversible gel, as a space-maintain approach, with a similar indication and goal as described for GBR with resorbable membranes [221]. The resorbable polymeric thermo-reversible gel was manufactured from a specific mixture of poloxamers dissolved in water (predominantly poloxamer 407) [221]. After examining the results of the 11 patients participating in the study, new bone formation was reported between 54% to 60%, without the appearance of fibrous tissue. Radiographic evaluation showed more than 10 mm height of new bone in all cases, after a six-month follow-up. Based on the clinical outcomes, cost-effectiveness and simplicity of the technique, it is considered one of the best techniques for the maxillary sinus elevation procedure [221].

oundre



**Figure 7**. (**A**) General step-by-step procedural diagram for a GBR/GTR procedure. Treatment begins with a tooth extraction or tooth loss (i), bone graft placement (ii), barrier membrane placement for compartmentalization of tissues (iii), and closure (when applicable/possible) (iv). Reproduced with permission from Ref [207]. Copyright 2018 Rodriguez IA. (**B**) Maxillofacial osteosynthesis system using third-generation bioactive/bioresorbable materials (Osteotrans  $MX^{(B)}$ ); (**C**) Bioresorbable sheet and tack fixation for right orbital reconstruction in a case with naso-orbito-ethmoidal (midfacial) fractures using the SuperFIXORB-MX<sup>(B)</sup> (OsteotransMS<sup>(B)</sup>) system (**D**) Bioresorbable plate osteosynthesis of advancement mandibular BSSRO using the SuperFIXORB-MX<sup>(B)</sup> (OsteotransMS<sup>(B)</sup>) system in orthognathic surgery. Reproduced with permission from Ref [172]. Copyright 2018, with permission from Elsevier. Application of commercial mesh and patch in tendon-to-bone interface repair: (**E**) Pitch-Patch graft is designed for reinforcement of the rotator cuff as a non-absorbable graft, sutured via multiple sutures directly to rotator cuff tissue. The designed suture holes in Pitch-Patch resist suture cut-through. (**F**) CelGro<sup>TM</sup> for augment repair of rotator cuff tears. Torn tendon must be trimmed and anchored with sutures back into healthy bone before placing the CelGro<sup>TM</sup>. Then, CelGro<sup>TM</sup> can

be trimmed to size and placed over the repair site to promote tendon healing. Reproduced with permission from Ref [72]. Copyright 2022 The Authors.

### 7.6. Other clinical applications of resorbable meshes

Besides the well-documented clinical trials related to dental and maxillofacial applications, meshes consisting of natural or synthetic polymers have other clinical tissue regeneration applications, such as breast surgery, and nerve, and tendon repair. Tissue stretches and concomitant unpleasant appearance and dissatisfaction is a common complication of breast implant surgery. This led to the use of resorbable meshes in soft tissue augmentation such as gradually resorbing P4HB-based GalaFlex<sup>®</sup> or the slower resorption PDX, both proved to be safe and efficiently maintained the mechanical strength and increased patient satisfaction without notable complications, malposition or ptosis [156, 222].

Peripheral nerve injuries are common on the upper extremities resulting in motor or sensory loss and consequently, limited daily activities. Nerve repair is performed with microsutures or if the nerve defect is extensive, nerve grafts could be used with limited effectiveness and persistent loss of function. To overcome this problem, resorbable materials were used in these injuries, ensuring the induction of the regeneration process, but absent by the time it could interrupt normal healing [223]. Based on preclinical results, poly[(R)-3-hydroxybutyrate (PHB) was used in ulnar and/or median nerve injury patients and found to be safe with very few complications and at least as effective as the conventional treatment since considerable improvement was seen in some sensory, motor and overall functional assessments in the PHB patients compared to epineural suture treatment recipients [223]. Furthermore, several bioresorbable nerve conduits (such as polyglycolic mesh – Neurotube, porcine collagen – Rovolnerve etc.) have received FDA or CE approval and showed impressive sensory outcomes

(75% of the cases were rated as good to excellent) following reconstruction of the resorbable polymers [224].

Tendons play a significant role in transmitting loads between musculoskeletal tissues. The repair of injured tendons typically involves biocompatible materials and surgical reparative techniques using a commercially available artificial tendon, being the most common clinical treatment. Tendon scaffolds can be based on absorbable and non-absorbable materials [96]. Poly-Tape mesh (Neoligaments Ltd., UK) is manufactured by weaving the non-absorbable polyethylene terephthalate (PET) fibers and is particularly used for rotator cuff tears (RCTs) repair (Figure 7E). While the open woven structure of Poly-Tape supports space for tissue ingrowth, the parallel fibers provide high strength (average tensile strength for the medium and larger patches are over 400 N and 550 N, respectively) [72]. On the other hand, natural resorbable biomaterials have resulted in better biological outcomes. Recently, CelGro™ (Orthocell Ltd.), a type I collagen bilayer membrane, was used in a clinical study to regenerate RCTs, indicating that the membrane is promising for induction of tendogenesis into the healing areas of tendon and tendon-bone interfaces (Figure 7F) [72, 225]. However, this scaffold is not recommended as a structural graft because of the low tensile strength (average ultimate tensile strength of 0.35  $\pm$  0.06 MPa; failure force of 5.4  $\pm$  0.38 N) in some specific tendon repair applications [72].

### 8. Conclusion and future perspectives

With the rapid development of polymer material science, resorbable meshes have gained attention in clinical studies. Before clinical adaptation, preclinical safety and feasibility studies are essential and inevitable. The main benefits of resorbable materials are the avoidable second surgery for the removal of the implant and the long-term inflammatory reactions initiated by the

permanent inserts along with the lack of systemic effects. Avoiding the second surgery also causes less discomfort to the patient, and it can potentially decrease the economic burden; however, it must be noted that resorbable polymer meshes and plates are more expensive compared to non-resorbable devices. Nevertheless, the cost of resorbable meshes usually outvalues the burden of mesh failure associated with the high rate of non-resorbable mesh removal and morbidity, mainly due to prosthesis infection. Indeed, material biocompatibility is a key factor guiding successful mesh implantation. Using resorbable polymer meshes and plates is favorable in pediatric cases, especially in cranio-maxillofacial reconstruction procedures. In clinical applications, resorbable polymer devices are well-visible on radiographic images, and they do not produce artefacts.

In the last few years, the use of resorbable polymers has progressively increased in soft and hard tissue applications with impressive results. However, most of the studies were performed on a small sample size, with relatively short follow-up periods. Consequently, large, multicenter studies are needed to assess the real benefits and long-term effects of implantable resorbable devices, with a special focus on materials enhanced with bioactive supplements. Such studies would expectedly provide enough data essential for well-consolidated decision making in the clinical setting. Surgeons can make more informed decisions for mesh selection based on the obtained knowledge of mesh material, construct weight as well as the patient's medical history, the overall status of the immune system, the origin of the disease and the nature of tissue defect.

The progressive demand for bioresorbable meshes with optimal functionality and behavior in interfacial tissues has led to the constant development and improvement of biomaterials. Hydrogel barriers, drug-loaded surface coatings, nanofibrous mats and modifications with nanoparticles have produced very promising outcomes *in vivo* animal models of the mesh.

Despite many efforts in this field, there is no ideal bioresorbable hernia mesh with a minimal recurrence rate, post-infection, and tissue adhesion. Thus, current studies focus on developing multi-functional bioresorbable meshes to address the main complications in clinical studies, mostly biocompatibility, enhanced mechanical performance, anti-adhesion, and infection prevention. The next generation of the mesh will be based on advanced prosthetic biomaterials that are fully resorbable in the long term facilitating tissue regeneration and combating infection in the surgical site through controlling the release of drugs after implantation. Surface modification of the resorbable meshes to achieve anti-adhesion features should be investigated using more efficient nanoparticles, hydrogels, or therapeutically active agents. Smart or stimuliresponsive biomaterials should receive more attention for tissue regeneration. By incorporating stimuli-responsive biomaterials, 4D-printed surgical meshes can be designed to change geometry over time. Such advancements will enable the mesh to dynamically adapt to the surrounding tissues post-implantation, improving tissue integration, reducing the risk of mesh displacement, and reinforcing abdominal walls. Furthermore, the incorporation of the "time" factor to MEW scaffolds by using shape memory biopolymers can unlock new capabilities and features in hernia mesh applications. MEW enables the fabrication of microfibrous meshes with precise control over structure and drug delivery, while 4D printing offers shape-changing adaptability to the mesh. These technologies have the potential to improve tissue regeneration procedures fundamentally by offering functionalized, personalized, and biocompatible bioresorbable meshes, which enhance patient outcomes and long-term success rates. In addition, the combination of appropriate surgical procedures and optimal meshes based on the specific requirements of the patients can overcome the current treatment complications. Furthermore, the outcomes on large animal models are essential to evaluate the complete biofunctionality of the

advanced bioresorbable mesh before clinical phase studies. Finally, the complexity of advanced bio-fabrication techniques and biomaterials with the integration of therapeutic agents will not only be technically challenging but also need specific consideration of regulatory approval pathways.

#### **Declaration of competing interest**

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Minghao Zheng is a consultant to Orthocell Ltd and holds stock in the company.

# Acknowledgments

This the project **MEBioSys** publication supported by with was reg. no. CZ.02.01.01/00/22\_008/0004634, co-funded by the ERDF as part of the MŠMT and the funding received from the V4-Korea 2023 Joint Call. Project no. 2022-2.1.1-NL-2022-00012 has been implemented with the support provided by the Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund, financed under the Cooperative Technology National Laboratory funding scheme. The authors also gratefully acknowledge funding from the Australian Research Council (IC170100061) through the Centre for Personalised Therapeutics Technologies.

#### Data availability

The data described in the article are available at https://zenodo.org/records/10246001. We would appreciate if other researchers could benefit from our literature and results. This will foster discussions and collaboration among scientists worldwide.

### References

[1] F. Corduas, D.A. Lamprou, E. Mancuso, Next-generation surgical meshes for drug delivery and tissue engineering applications: materials, design and emerging manufacturing technologies, Bio-Design and Manufacturing 4(2) (2021) 278-310.

[2] E. Mancuso, C. Downey, E. Doxford - Hook, M.G. Bryant, P. Culmer, The use of polymeric meshes for pelvic organ prolapse: Current concepts, challenges, and future perspectives, Journal of Biomedical Materials Research Part B: Applied Biomaterials 108(3) (2020) 771-789.

[3] H. Perry, Implantations of silver filigree for cure of large ventral hernia; report of two cases, The Boston Medical and Surgical Journal 151(4) (1904) 97-99.

[4] K. Baylón, P. Rodríguez-Camarillo, A. Elías-Zúñiga, J.A. Díaz-Elizondo, R. Gilkerson, K. Lozano, Past, Present and Future of Surgical Meshes: A Review, Membranes (Basel) 7(3) (2017).

[5] H. Wang, B. Klosterhalfen, U. Klinge, A. Müllen, S. Jockenhoevel, Influence of polypropylene mesh degradation on tissue inflammatory reaction, Journal of Biomedical Materials Research Part A 111(8) (2023) 1110-1119.

[6] L.J. Cook, T. Kovacs, Novel devices for implant-based breast reconstruction: is the use of meshes to support the lower pole justified in terms of benefits? A review of the evidence, Ecancermedicalscience 12 (2018) 796.

[7] K. Baylon, P. Rodriguez-Camarillo, A. Elias-Zuniga, J.A. Diaz-Elizondo, R. Gilkerson, K. Lozano, Past, Present and Future of Surgical Meshes: A Review, Membranes (Basel) 7(3) (2017).

[8] E. Mancuso, C. Downey, E. Doxford-Hook, M.G. Bryant, P. Culmer, The use of polymeric meshes for pelvic organ prolapse: Current concepts, challenges, and future perspectives, J Biomed Mater Res B Appl Biomater 108(3) (2020) 771-789.

[9] C. Wang See, T. Kim, D. Zhu, Hernia Mesh and Hernia Repair: A Review, Engineered Regeneration 1 (2020) 19-33.

[10] T.N. Robinson, J.H. Clarke, J. Schoen, M.D. Walsh, Major mesh-related complications following hernia repair: events reported to the Food and Drug Administration, Surgical Endoscopy and Other Interventional Techniques 19 (2005) 1556-1560.

[11] A. Wood, M. Cozad, D. Grant, A. Ostdiek, S. Bachman, S. Grant, Materials characterization and histological analysis of explanted polypropylene, PTFE, and PET hernia meshes from an individual patient, Journal of Materials Science: Materials in Medicine 24 (2013) 1113-1122.
[12] B.N. Brown, D. Mani, A.L. Nolfi, R. Liang, S.D. Abramowitch, P.A. Moalli,

Characterization of the host inflammatory response following implantation of prolapse mesh in rhesus macaque, American Journal of Obstetrics and Gynecology 213(5) (2015) 668. e1-668. e10.

[13] S. Kalaba, E. Gerhard, J.S. Winder, E.M. Pauli, R.S. Haluck, J. Yang, Design strategies and applications of biomaterials and devices for Hernia repair, Bioactive Materials 1(1) (2016) 2-17. [14] J.F. FitzGerald, A.S. Kumar, Biologic versus Synthetic Mesh Reinforcement: What are the Pros and Cons?, Clin Colon Rectal Surg 27(4) (2014) 140-8.

[15] M. Ackermann, X. Wang, S. Wang, M. Neufurth, H.C. Schroder, F.E. Isemer, W.E.G. Muller, Collagen-inducing biologization of prosthetic material for hernia repair: Polypropylene meshes coated with polyP/collagen, J Biomed Mater Res B Appl Biomater 106(6) (2018) 2109-2121.

[16] F. Marinaro, J.M. Silva, A.A. Barros, I.M. Aroso, J.C. Gómez-Blanco, I. Jardin, J.J. Lopez, M. Pulido, M. de Pedro, R.L. Reis, F.M. Sánchez-Margallo, J.G. Casado, E. López, A Fibrin Coating Method of Polypropylene Meshes Enables the Adhesion of Menstrual Blood-Derived Mesenchymal Stromal Cells: A New Delivery Strategy for Stem Cell-Based Therapies, Int J Mol Sci 22(24) (2021).

[17] R. Raj, S.J. Shenoy, M.P. Mony, K.V. Pratheesh, R.S. Nair, C.S. Geetha, P.K. Sobhan, C. Purnima, T.V. Anilkumar, Surface Modification of Polypropylene Mesh with a Porcine Cholecystic Extracellular Matrix Hydrogel for Mitigating Host Tissue Reaction, ACS Applied Bio Materials 4(4) (2021) 3304-3319.

[18] R. Blazquez, F.M. Sanchez-Margallo, V. Alvarez, A. Uson, J.G. Casado, Surgical meshes coated with mesenchymal stem cells provide an anti-inflammatory environment by a M2 macrophage polarization, Acta Biomater 31 (2016) 221-230.

[19] O. Protsepko, P. Voisard, C. Kuhn, A. Maccagno, C. Dannecker, U. Jeschke, F. Pauli, F. Garrido, Induction of a different immune response in non-titanized compared to titanized polypropylene meshes, Acta Biomater 169 (2023) 363-371.

[20] Y. Xiao, X. Zuo, H. Li, Y. Zhao, X. Wang, Impact of titanium-coated polypropylene mesh on functional outcome and quality of life after inguinal hernia repair, Heliyon 9(7) (2023) e17691.

[21] Q. Li, L. Wang, L. Yu, C. Li, X. Xie, H. Yan, W. Zhou, C. Wang, Z. Liu, G. Hou, Y.-Q. Zhao, Polysaccharide-Based Coating with Excellent Antibiofilm and Repeatable Antifouling-Bactericidal Properties for Treating Infected Hernia, Biomacromolecules 25(2) (2024) 1180-1190.

[22] Y. Mao, Q. Wang, H. Zhang, Y. Li, L. Wang, Zwitterion mediated anti-protein adsorption on polypropylene mesh to reduce inflammation for efficient hernia repair, Biomater Adv 158 (2024) 213769.

[23] T. Saha, S. Houshyar, S. Ranjan Sarker, S. Ghosh, C. Dekiwadia, R. Padhye, X. Wang, Surface-Functionalized Polypropylene Surgical Mesh for Enhanced Performance and Biocompatibility, ACS Applied Bio Materials 2(12) (2019) 5905-5915.

[24] C.Y. Kong, L.L. Lai, A.Y Y. Khoo, N.A. Rahman, K.F. Chin, Inflammatory reaction to fish oil coated polypropylene mesh used for laparoscopic incisional hernia repair: a case report, BMC surgery 16 (2016) 1-6.

[25] M.H.F. Schreinemacher, K.W.Y. van Barneveld, R.E.G. Dikmans, M.J.J. Gijbels, J.-W.M. Greve, N.D. Bouvy, Coated meshes for hernia repair provide comparable intraperitoneal adhesion prevention, Surgical Endoscopy 27(11) (2013) 4202-4209.

[26] M. Yucel, B. Gurhan, F. Basak, A. Ozpek, E. Unal, A. Kilic, Omega-3 fatty acid covered polypropylene mesh for abdominal wall hernia repair: a prospective analysis of 30 patients, Cukurova Medical Journal 42(2) (2017) 314-19.

[27] G. Passot, J. Margier, A. Kefleyesus, P. Rousset, P. Ortega-Deballon, Y. Renard, S. Bin, L. Villeneuve, Slowly absorbable mesh versus standard care in the management of contaminated midline incisional hernia (COMpACT-BIO): a multicentre randomised controlled phase III trial including a health economic evaluation, BMJ Open 12(8) (2022) e061184.

[28] S. Morales-Conde, P. Hernández-Granados, L. Tallón-Aguilar, M. Verdaguer-Tremolosa, M. López-Cano, Ventral hernia repair in high-risk patients and contaminated fields using a single mesh: proportional meta-analysis, Hernia 26(6) (2022) 1459-1471.

[29] G. Pascual, S. Sotomayor, M. Rodriguez, B. Pérez-Köhler, J.M. Bellon, Repair of abdominal wall defects with biodegradable laminar prostheses: polymeric or biological?, PLoS One 7(12) (2012) e52628.

[30] C.R. Deeken, B.J. Eliason, M.D. Pichert, S.A. Grant, M.M. Frisella, B.D. Matthews, Differentiation of biologic scaffold materials through physicomechanical, thermal, and enzymatic degradation techniques, Annals of surgery 255(3) (2012) 595-604.

[31] N.G. Menon, E.D. Rodriguez, C.K. Byrnes, J.A. Girotto, N.H. Goldberg, R.P. Silverman, Revascularization of human acellular dermis in full-thickness abdominal wall reconstruction in the rabbit model, Annals of plastic surgery 50(5) (2003) 523-527.

[32] J. Chen, J. Xu, A. Wang, M. Zheng, Scaffolds for tendon and ligament repair: review of the efficacy of commercial products, Expert review of medical devices 6(1) (2009) 61-73.

[33] S. Mazzola Poli de Figueiredo, L. Tastaldi, R.-M.D. Mao, D.L. Lima, L.-C. Huang, R. Lu, Biologic versus synthetic mesh in open ventral hernia repair: A systematic review and metaanalysis of randomized controlled trials, Surgery 173(4) (2023) 1001-1007.

[34] S. Kamarajah, S. Chapman, J. Glasbey, D. Morton, N. Smart, T. Pinkney, A. Bhangu, Systematic review of the stage of innovation of biological mesh for complex or contaminated abdominal wall closure, BJS open 2(6) (2018) 371-380.

[35] M. Miserez, A.P. Jairam, G.S.A. Boersema, Y. Bayon, J. Jeekel, J.F. Lange, Resorbable Synthetic Meshes for Abdominal Wall Defects in Preclinical Setting: A Literature Review, J Surg Res 237 (2019) 67-75.

[36] M. Vert, Bioresorbable Polymers for Temporary Therapeutic Applications, Angew Makromol Chem 166 (1989) 155-168.

[37] S. Hajebi, S.M. Nasr, N. Rabiee, M. Bagherzadeh, S. Ahmadi, M. Rabiee, M. Tahriri, L. Tayebi, M.R. Hamblin, Bioresorbable composite polymeric materials for tissue engineering applications, Int J Polym Mater Po 70(13) (2021) 926-940.

[38] N. Huebsch, D.J. Mooney, Inspiration and application in the evolution of biomaterials, Nature 462(7272) (2009) 426-32.

[39] L.S. Nair, C.T. Laurencin, Biodegradable polymers as biomaterials, Prog Polym Sci 32(8-9) (2007) 762-798.

[40] S. Ullah, X. Chen, Fabrication, applications and challenges of natural biomaterials in tissue engineering, Applied Materials Today 20 (2020) 100656.

[41] M. Volpi, A. Paradiso, M. Costantini, W. Swie, Hydrogel-Based Fiber Biofabrication Techniques for Skeletal Muscle Tissue Engineering, Acs Biomaterials Science & Engineering 8(2) (2022) 379-405.

[42] A. Kirillova, R. Maxson, G. Stoychev, C.T. Gomillion, L. Ionov, 4D Biofabrication Using Shape-Morphing Hydrogels, Adv Mater 29(46) (2017).

[43] A.S. Pandit, J.A. Henry, Design of surgical meshes - an engineering perspective, Technol Health Care 12(1) (2004) 51-65.

[44] S. Bringman, J. Conze, D. Cuccurullo, J. Deprest, K. Junge, B. Klosterhalfen, E. Parra-Davila, B. Ramshaw, V. Schumpelick, Hernia repair: the search for ideal meshes, Hernia 14(1) (2010) 81-7.

[45] K. Baylón, P. Rodríguez-Camarillo, A. Elías-Zúñiga, J.A. Díaz-Elizondo, R. Gilkerson, K. Lozano, Past, Present and Future of Surgical Meshes: A Review, Membranes-Basel 7(3) (2017).
[46] U. Klinge, J.-K. Park, B. Klosterhalfen, 'The Ideal Mesh?', Pathobiology 80(4) (2013) 169-175.

[47] S. Todros, P.G. Pavan, A.N. Natali, Synthetic surgical meshes used in abdominal wall surgery: Part I—Materials and structural conformation, Journal of Biomedical Materials Research Part B: Applied Biomaterials 105(3) (2017) 689-699.

[48] H. Salgaonkar, D. Lomanto, Mesh technology—an update, Annals of Laparoscopic and Endoscopic Surgery 3(10) (2018).

[49] W. Liu, Y. Xie, Y. Zheng, W. He, K. Qiao, H. Meng, Regulatory science for hernia mesh: Current status and future perspectives, Bioact Mater 6(2) (2021) 420-432.

[50] <3 CDRH-Regulatory-Science-Priorities-Report-2018\_0.pdf>.

[51] U.S.F.A.D. ADMINISTRATION, CFR - Code of Federal Regulations Title 21

Electronic Code of Federal Regulations (eCFR), 2023.

[52] K. Keltie, S. Elneil, A. Monga, H. Patrick, J. Powell, B. Campbell, A.J. Sims, Complications following vaginal mesh procedures for stress urinary incontinence: an 8 year study of 92,246 women, Sci Rep-Uk 7 (2017).

[53] R. Ajdary, G. Reyes, J. Kuula, E. Raussi-Lehto, T.S. Mikkola, E. Kankuri, O.J. Rojas, Direct ink writing of biocompatible nanocellulose and chitosan hydrogels for implant mesh matrices, ACS polymers Au 2(2) (2021) 97-107.

[54] M.J. Dewey, A.V. Nosatov, K. Subedi, R. Shah, A. Jakus, B.A.C. Harley, Inclusion of a 3Dprinted Hyperelastic Bone mesh improves mechanical and osteogenic performance of a mineralized collagen scaffold, Acta Biomater 121 (2021) 224-236.

[55] J.Y. Ren, R. Murray, C.S. Wong, J.L. Qin, M. Chen, M. Totsika, A.D. Riddell, A. Warwick, N. Rukin, M.A. Woodruff, Development of 3D Printed Biodegradable Mesh with Antimicrobial Properties for Pelvic Organ Prolapse, Polymers-Basel 14(4) (2022).

[56] J.A. Hubbell, Biomaterials in tissue engineering, Biotechnology (N Y) 13(6) (1995) 565-76.[57] V.G. Muir, J.A. Burdick, Chemically Modified Biopolymers for the Formation of

Biomedical Hydrogels, Chem Rev 121(18) (2021) 10908-10949.

[58] B.S. Kim, C.E. Baez, A. Atala, Biomaterials for tissue engineering, World J Urol 18(1) (2000) 2-9.

[59] B.P. Chan, K.W. Leong, Scaffolding in tissue engineering: general approaches and tissuespecific considerations, Eur Spine J 17 Suppl 4(Suppl 4) (2008) 467-79.

[60] M.P. Lutolf, J.A. Hubbell, Synthetic biomaterials as instructive extracellular

microenvironments for morphogenesis in tissue engineering, Nat Biotechnol 23(1) (2005) 47-55.

[61] A. Kurella, N.B. Dahotre, Review paper: surface modification for bioimplants: the role of laser surface engineering, J Biomater Appl 20(1) (2005) 5-50.

[62] J.C. Brodie, E. Goldie, G. Connel, J. Merry, M.H. Grant, Osteoblast interactions with calcium phosphate ceramics modified by coating with type I collagen, J Biomed Mater Res A 73(4) (2005) 409-21.

[63] R.U. Hartung, Biomaterials for inguinal hernia repair, Springer, 2020, pp. 77-82.[64] J. Skandalakis, G.L. Colborn, L.J. Skandalakis, D. McClusky, Historic aspects of groin heria repair, Nyhus and Condon's Hernia 39 (2002) 29-43.

[65] A. Pans, P. Elen, W. Dewé, C. Desaive, Long-term results of polyglactin mesh for the prevention of incisional hernias in obese patients, World Journal of Surgery 22(5) (1998) 479-483.

[66] K. Baylón, P. Rodríguez-Camarillo, A. Elías-Zúñiga, J.A. Díaz-Elizondo, R. Gilkerson, K. Lozano, Past, present and future of surgical meshes: A review, Membranes 7(3) (2017) 47-47.
[67] T. Saha, X. Wang, R. Padhye, S. Houshyar, A review of recent developments of polypropylene surgical mesh for hernia repair, OpenNano 7 (2022) 100046.

[68] M. Rodríguez, V. Gómez-Gil, B. Pérez-Köhler, G. Pascual, J.M. Bellón, Polymer hernia repair materials: Adapting to patient needs and surgical techniques, Materials 14(11) (2021) 2790-2790.

[69] Á. Serrano - Aroca, S. Pous - Serrano, Prosthetic meshes for hernia repair: State of art, classification, biomaterials, antimicrobial approaches, and fabrication methods, Journal of Biomedical Materials Research Part A 109(12) (2021) 2695-2719.

[70] F. Ruiz-Jasbon, J. Norrby, M.L. Ivarsson, S. Björck, Inguinal hernia repair using a synthetic long-term resorbable mesh: results from a 3-year prospective safety and performance study, Hernia 18(5) (2014) 723-730.

[71] H. Hjort, T. Mathisen, A. Alves, G. Clermont, J.P. Boutrand, Three-year results from a preclinical implantation study of a long-term resorbable surgical mesh with time-dependent mechanical characteristics, Hernia 16(2) (2012) 191-197.

[72] B. Shiroud Heidari, R. Ruan, E. Vahabli, P. Chen, E.M. De-Juan-Pardo, M. Zheng, B. Doyle, Natural, synthetic and commercially-available biopolymers used to regenerate tendons and ligaments, Bioactive Materials 19 (2023) 179-197.

[73] B. Shiroud Heidari, E. Muiños Lopez, E. Harrington, R. Ruan, P. Chen, S.M. Davachi, B. Allardyce, R. Rajkhowa, R. Dilley, F. Granero-Moltó, E.M. De-Juan-Pardo, M. Zheng, B. Doyle, Novel hybrid biocomposites for tendon grafts: The addition of silk to polydioxanone and poly(lactide-co-caprolactone) enhances material properties, in vitro and in vivo biocompatibility, Bioactive Materials 25 (2023) 291-306.

[74] W. Gong, T. Cheng, Q. Liu, Q. Xiao, J. Li, Surgical repair of abdominal wall defect with biomimetic nano/microfibrous hybrid scaffold. Materials Science and Engineering C 93 (2018) 828-837.

[75] A.L. Rivera-Briso, F.L. Aachmann, V. Moreno-Manzano, Á. Serrano-Aroca, Graphene oxide nanosheets versus carbon nanofibers: Enhancement of physical and biological properties of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) films for biomedical applications, International Journal of Biological Macromolecules 143 (2020) 1000-1008.

[76] L. Almany, D. Seliktar, Biosynthetic hydrogel scaffolds made from fibrinogen and polyethylene glycol for 3D cell cultures, Biomaterials 26(15) (2005) 2467-2477.

[77] M.M. Martino, F. Tortelli, M. Mochizuki, S. Traub, D. Ben-David, G.A. Kuhn, R. Muller, E. Livne, S.A. Eming, J.A. Hubbell, Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing, Sci Transl Med 3(100) (2011) 100ra89.

[78] M.P. Lutolf, J.L. Lauer-Fields, H.G. Schmoekel, A.T. Metters, F.E. Weber, G.B. Fields, J.A. Hubbell, Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics, Proc Natl Acad Sci U S A 100(9) (2003) 5413-8.

[79] A. Sionkowska, Current research on the blends of natural and synthetic polymers as new biomaterials: Review, Prog Polym Sci 36(9) (2011) 1254-1276.

[80] Y. Gao, X. Han, J. Chen, Y. Pan, M. Yang, L. Lu, J. Yang, Z. Suo, T. Lu, Hydrogel-mesh composite for wound closure, Proc Natl Acad Sci U S A 118(28) (2021).

[81] S.P. Nikam, Y.H. Hsu, J.R. Marks, C. Mateas, N.C. Brigham, S.M. McDonald, D.S. Guggenheim, D. Ruppert, J.I. Everitt, H. Levinson, M.L. Becker, Anti-adhesive bioresorbable elastomer-coated composite hernia mesh that reduce intraperitoneal adhesions, Biomaterials 292 (2023) 121940.

[82] E. Stocco, S. Barbon, A. Emmi, C. Tiengo, V. Macchi, R. De Caro, A. Porzionato, Bridging Gaps in Peripheral Nerves: From Current Strategies to Future Perspectives in Conduit Design, International journal of molecular sciences 24(11) (2023).

[83] M. Allaeys, L. Visscher, F.P.J. Den Hartog, P.J. Tanis, J. Jeekel, J.F. Lange, F. Berrevoet, H.H. Eker, CLOSURE STRENGTH OF SUTURE TECHNIQUES AND SUTURE

MATERIALS, British Journal of Surgery 110 (2023) ii16-ii17.

[84] E. Ostroff, K. Parekh, A. Prominski, B. Tian, Biocompatible and Nanoenabled Technologies for Biological Modulation, Advanced Materials Technologies 7(2) (2021).

[85] D. Xu, M. Fang, Q. Wang, Y. Qiao, Y. Li, L. Wang, Latest Trends on the Attenuation of Systemic Foreign Body Response and Infectious Complications of Synthetic Hernia Meshes, ACS Applied Bio Materials 5(1) (2022) 1-19.

[86] W. Hu, S. Lu, Y. Ma, P. Ren, X. Ma, N. Zhou, T. Zhang, Z. Ji, Poly(dopamine)-inspired surface functionalization of polypropylene tissue mesh for prevention of intra-peritoneal adhesion formation, Journal of Materials Chemistry B 5(3) (2017) 575-585.

[87] C. Lai, K.S. Hu, Q.L. Wang, L.Y. Sheng, S.J. Zhang, Y. Zhang, Anti-Adhesion Mesh for Hernia Repair Based on Modified Bacterial Cellulose, Starch/Staerke 70(11-12) (2018) 1700319-1700319.

[88] U. Aydemir Sezer, V. Sanko, M. Gulmez, E. Sayman, B. Aru, Z.N. Yuksekdag, A. Aktekin, F. Vardar Aker, S. Sezer, A polypropylene-integrated bilayer composite mesh with bactericidal and antiadhesive efficiency for hernia operations, ACS Biomaterials Science & Engineering 3(12) (2017) 3662-3674.

[89] Z. Chen, Y. Zhao, T. He, K. Chen, L. Jiang, J. Zhang, H. Wan, R. Li, Study on the prevention of postoperative intraperitoneal adhesion of rat with PLGA/PEG electrospun polymer membrane, Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 31(8) (2017) 999-1005.

[90] M.G. Sabbieti, A. Dubbini, F. Laus, E. Paggi, A. Marchegiani, M. Capitani, L. Marchetti, F. Dini, T. Vermonden, P. Di Martino, D. Agas, R. Censi, In vivo biocompatibility of p(HPMAmlac)-PEG hydrogels hybridized with hyaluronan, Journal of tissue engineering and regenerative medicine 11(11) (2017) 3056-3067.

[91] P.C. Chen, Y.P. Chen, C.C. Wu, C.C. Tseng, C.Y. Yang, Y.W. Hung, Z.H. Wen, A resorbable hyaluronic acid hydrogel to prevent adhesion in porcine model under laparotomy pelvic surgery, Journal of Applied Biomaterials and Functional Materials 18 (2020).

[92] S. Lu, W. Hu, Z. Zhang, Z. Ji, T. Zhang, Sirolimus-coated, poly (L-lactic acid)-modified polypropylene mesh with minimal intra-peritoneal adhesion formation in a rat model, Hernia 22 (2018) 1051-1060.

[93] S. Lanzalaco, C. Weis, K.A. Traeger, P. Turon, C. Alemán, E. Armelin, Mechanical Properties of Smart Polypropylene Meshes: Effects of Mesh Architecture, Plasma Treatment, Thermosensitive Coating, and Sterilization Process, ACS biomaterials science & engineering 9(6) (2023) 3699-3711.

[94] T. Zhang, Z. Zhang, W. Hu, Z. Ji, N. Gu, Preparation of poly(vinyl alcohol) modified polypropylene mesh and its antiadhesion efficacy in experimental hernia repair, Colloids and Surfaces A: Physicochemical and Engineering Aspects 500 (2016) 10-16.

[95] D. Wei, Y. Huang, M. Liang, P. Ren, Y. Tao, L. Xu, T. Zhang, Z. Ji, Q. Zhang, Polypropylene composite hernia mesh with anti-adhesion layer composed of PVA hydrogel and liposomes drug delivery system, Colloids and Surfaces B: Biointerfaces 223 (2023) 113159. [96] B. Shiroud Heidari, R. Ruan, E.M. De-Juan-Pardo, M. Zheng, B. Doyle, Biofabrication and signaling strategies for tendon/ligament interfacial tissue engineering, ACS Biomaterials Science & Engineering 7(2) (2021) 383-399.

[97] U. Aydemir Sezer, V. Sanko, M. Gulmez, B. Aru, E. Sayman, A. Aktekin, F. Vardar Aker, G. Yanikkaya Demirel, S. Sezer, Polypropylene composite hernia mesh with anti-adhesion layer composed of polycaprolactone and oxidized regenerated cellulose, Materials Science and Engineering C 99 (2019) 1141-1152.

[98] Y. Mao, Y. Meng, S. Li, Y. Li, R. Guidoin, F. Wang, Y. Qiao, G. Brochu, Z. Zhang, J. Tang, Alginate-assistant nanofiber integrated with polypropylene hernia mesh for efficient antiadhesion effects and enhanced tissue compatibility, Composites Part B: Engineering 235 (2022) 109761.

[99] J.M. Dodda, M.G. Azar, P. Belsky, M. Slouf, V. Gajdosová, P.B. Kasi, L.O. Anerillas, T. Kovárík, Bioresorbable films of polycaprolactone blended with poly(lactic acid) or poly(lacticco-glycolic acid), Int J Biol Macromol 248 (2023).

[100] M. Shokrollahi, S.H. Bahrami, M.H. Nazarpak, A. Solouk, Biomimetic double-sided polypropylene mesh modified by DOPA and ofloxacin loaded carboxyethyl chitosan/polyvinyl alcohol-polycaprolactone nanofibers for potential hernia repair applications, International Journal of Biological Macromolecules 165 (2020) 902-917.

[101] W. Hu, S. Lu, Y. Ma, P. Ren, X. Ma, N. Zhou, T. Zhang, Z. Ji, Poly (dopamine)-inspired surface functionalization of polypropylene tissue mesh for prevention of intra-peritoneal adhesion formation, Journal of materials chemistry B 5(3) (2017) 575-585.

[102] S. Kalaba, E. Gerhard, J.S. Winder, E.M. Pauli, R.S. Haluck, J. Yang, Design Strategies and Applications of Biomaterials and Devices for Hernia Repair, Bioact Mater 1(1) (2016) 2-17. [103] S. Houshyar, A. Sarker, A. Jadhav, G.S. Kumar, A. Bhattacharyya, R. Nayak, R.A. Shanka, T. Saha, A. Pifoi, P. Padhya, K. Fox, Polymorphilane panediamond composite for hernia

Shanks, T. Saha, A. Rifai, R. Padhye, K. Fox, Polypropylene-nanodiamond composite for hernia mesh, Mater Sci Eng C Mater Biol Appl 111 (2020) 110780.

[104] M. He, H. Jiang, R. Wang, Y. Xie, W. Zhao, C. Zhao, A versatile approach towards multifunctional surfaces via covalently attaching hydrogel thin layers, J Colloid Interface Sci 484 (2016) 60-69.

[105] A. Prudente, C.L. Riccetto, M.M. Simoes, B.M. Pires, M.G. de Oliveira, Impregnation of implantable polypropylene mesh with S-nitrosoglutathione-loaded poly(vinyl alcohol), Colloids Surf B Biointerfaces 108 (2013) 178-84.

[106] N. Sanbhal, Y. Li, A. Khatri, M. Peerzada, L. Wang, Chitosan Cross-Linked Bio-based Antimicrobial Polypropylene Meshes for Hernia Repair Loaded with Levofloxacin HCl via Cold Oxygen Plasma, Coatings 9(3) (2019).

[107] A. Serafim, S. Cecoltan, E. Olaret, D.M. Dragusin, E. Vasile, V. Popescu, B.S. Manolescu Mastalier, H. Iovu, I.C. Stancu, Bioinspired Hydrogel Coating Based on Methacryloyl Gelatin Bioactivates Polypropylene Meshes for Abdominal Wall Repair, Polymers (Basel) 12(8) (2020).
[108] C.L. Romano, K. Malizos, N. Capuano, R. Mezzoprete, M. D'Arienzo, C. Van Der

Straeten, S. Scarponi, L. Drago, Does an Antibiotic-Loaded Hydrogel Coating Reduce Early Post-Surgical Infection After Joint Arthroplasty?, J Bone Jt Infect 1 (2016) 34-41.

[109] J. Sahoo, S. Sarkhel, N. Mukherjee, A. Jaiswal, Nanomaterial-Based Antimicrobial Coating for Biomedical Implants: New Age Solution for Biofilm-Associated Infections, ACS Omega 7(50) (2022) 45962-45980.

[110] S. Yu, W.T. Shi, S. Houshyar, X. Wang, P.B. Ma, Preparation and performances of coated polypropylene hernia mesh with natural biomaterials, Colloid Interfac Sci 45 (2021).

[111] A. Serafim, S. Cecoltan, E. Olaret, D.M. Dragusin, E. Vasile, V. Popescu, B.S.M.
Mastalier, H. Iovu, I.C. Stancu, Bioinspired Hydrogel Coating Based on Methacryloyl Gelatin
Bioactivates Polypropylene Meshes for Abdominal Wall Repair, Polymers-Basel 12(8) (2020).
[112] R. Velez, E. Sloand, Combating antibiotic resistance, mitigating future threats and ongoing initiatives, Molecular Ecology 25(13-14) (2016) 1886-1889.

[113] D. Ren, H. Yi, W. Wang, X. Ma, The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation, Carbohydrate Research 340(15) (2005) 2403-2410.

[114] J. Reinbold, T. Hierlemann, L. Urich, A.K. Uhde, I. Müller, T. Weindl, U. Vogel, C. Schlensak, H.P. Wendel, S. Krajewski, Biodegradable rifampicin-releasing coating of surgical meshes for the prevention of bacterial infections, Drug Design, Development and Therapy 11 (2017) 2753-2762.

[115] O. Guillaume, J.P. Lavigne, O. Lefranc, B. Nottelet, J. Coudane, X. Garric, New antibiotic-eluting mesh used for soft tissue reinforcement, Acta Biomaterialia 7(9) (2011) 3390-3397.

[116] S. Ma, A. Adayi, Z. Liu, M. Li, M. Wu, L. Xiao, Y. Sun, Q. Cai, X. Yang, X. Zhang, P. Gao, Asymmetric collagen/chitosan membrane containing minocycline-loaded chitosan nanoparticles for guided bone regeneration, Scientific Reports 6(1) (2016) 31822-31822.

[117] L. Rong, D. Yang, B. Wang, D. Xiao, M. Lu, Z. Mao, H. Xu, Y. Gu, X. Feng, X. Sui, Durable and effective antibacterial cotton fabric collaborated with polypropylene tissue mesh for abdominal wall defect repair, ACS Biomaterials Science & Engineering 6(7) (2020) 3868-3877.
[118] E. Axibal, M. Brown, Surgical Dressings and Novel Skin Substitutes, Dermatologic Clinics 37(3) (2019) 349-366.

[119] G. Prado-Prone, P. Silva-Bermudez, A. Almaguer-Flores, J.A. García-Macedo, V.I. García, S.E. Rodil, C. Ibarra, C. Velasquillo, Enhanced antibacterial nanocomposite mats by coaxial electrospinning of polycaprolactone fibers loaded with Zn-based nanoparticles, Nanomedicine: Nanotechnology, Biology and Medicine 14(5) (2018) 1695-1706.

[120] E. Mancuso, C. Tonda-Turo, C. Ceresa, V. Pensabene, S.D. Connell, L. Fracchia, P. Gentile, Potential of Manuka Honey as a Natural Polyelectrolyte to Develop Biomimetic Nanostructured Meshes With Antimicrobial Properties, Frontiers in Bioengineering and Biotechnology 7 (2019) 344-344.

[121] Z. Muwaffak, A. Goyanes, V. Clark, A.W. Basit, S.T. Hilton, S. Gaisford, Patient-specific 3D scanned and 3D printed antimicrobial polycaprolactone wound dressings, International Journal of Pharmaceutics 527(1-2) (2017) 161-170.

[122] W.M. Metwally, S.E. El-Habashy, N.A. El-Nikhely, H.E. Mahmoud, H.M. Eltaher, L. El-Khordagui, Nano zinc oxide-functionalized nanofibrous microspheres: A bioactive hybrid platform with antimicrobial, regenerative and hemostatic activities, Int J Pharmaceut 638 (2023).
[123] A. Sobczak-Kupiec, D. Malina, M. Piatkowski, K. Krupa-Zuczek, Z. Wzorek, B. Tyliszczak, Physicochemical and biological properties of hydrogel/gelatin/hydroxyapatite PAA/G/HAp/AgNPs composites modified with silver nanoparticles, Journal of nanoscience and

nanotechnology 12(12) (2012) 9302-11.

[124] G.C. Ebersole, E.G. Buettmann, M.R. MacEwan, M.E. Tang, M.M. Frisella, B.D.
Matthews, C.R. Deeken, Development of novel electrospun absorbable polycaprolactone (PCL) scaffolds for hernia repair applications, Surgical endoscopy 26 (2012) 2717-2728.
[125] I.J.H. Barrientos, G.R. MacKenzie, C.G. Wilson, D.A. Lamprou, P. Coats, Biological

performance of electrospun polymer fibres, Materials 12(3) (2019) 363-363.

[126] I.J. Hall Barrientos, E. Paladino, S. Brozio, M.K. Passarelli, S. Moug, R.A. Black, C.G. Wilson, D.A. Lamprou, Fabrication and characterisation of drug-loaded electrospun polymeric nanofibers for controlled release in hernia repair, International Journal of Pharmaceutics 517(1-2) (2017) 329-337.

[127] B. Kheilnezhad, A. Hadjizadeh, Ibuprofen-Loaded Electrospun PCL/PEG Nanofibrous Membranes for Preventing Postoperative Abdominal Adhesion, ACS Applied Bio Materials 5(4) (2022) 1766-1778.

[128] S.M. Davachi, B.S. Heidari, V.A. Madormo, T.M. DeSpirito, E. Jabbari, Biocompatible Polymers for 3D Printing, EMERGING TECHNOLOGIES IN BIOPHYSICAL SCIENCES: A WORLD SCIENTIFIC REFERENCE: Volume 1: Emerging Technologies for Biofabrication and Biomanufacturing (2023) 63-101.

[129] B. Pérez-Köhler, S. Benito-Martínez, V. Gómez-Gil, M. Rodríguez, G. Pascual, J.M. Bellón, New insights into the application of 3d-printing technology in hernia repair, Materials 14(22) (2021) 7092-7092.

[130] F.J. Calero Castro, Y. Yuste, S. Pereira, M.D. Garvín, M.Á. López García, F.J. Padillo, F. de la Portilla, Proof of concept, design, and manufacture via 3 - D printing of a mesh with bactericidal capacity: Behaviour in vitro and in vivo, Journal of Tissue Engineering and Regenerative Medicine 13(11) (2019) 1955-1964.

[131] D.H. Ballard, J.A. Weisman, U. Jammalamadaka, K. Tappa, J.S. Alexander, F.D. Griffen, Three-dimensional printing of bioactive hernia meshes: In vitro proof of principle, Surgery (United States) 161(6) (2017) 1479-1481.

[132] W.M. Metwally, S.E. El-Habashy, L.S. El-Hosseiny, M.M. Essawy, H.M. Eltaher, L.K. El-Khordagui, Bioinspired 3D-printed scaffold embedding DDAB-nano ZnO/nanofibrous microspheres for regenerative diabetic wound healing, Biofabrication 16(1) (2024).

[133] N.T. Saidy, A. Fernández - Colino, B.S. Heidari, R. Kent, M. Vernon, O. Bas, S. Mulderrig, A. Lubig, J.C. Rodríguez - Cabello, B. Doyle, Spatially heterogeneous tubular scaffolds for in situ heart valve tissue engineering using melt electrowriting, Advanced Functional Materials 32(21) (2022) 2110716.

[134] T.M. Robinson, D.W. Hutmacher, P.D. Dalton, The next frontier in melt electrospinning: taming the jet, Advanced Functional Materials 29(44) (2019) 1904664.

[135] I. Liashenko, A. Hrynevich, P.D. Dalton, Designing outside the box: Unlocking the geometric freedom of melt electrowriting using microscale layer shifting, Advanced Materials 32(28) (2020) 2001874.

[136] J. Ren, R. Murray, C.S. Wong, J. Qin, M. Chen, M. Totsika, A.D. Riddell, A. Warwick, N. Rukin, M.A. Woodruff, Development of 3D Printed Biodegradable Mesh with Antimicrobial Properties for Pelvic Organ Prolapse, Polymers 14(4) (2022) 763-763.

[137] J. Lai, X. Ye, J. Liu, C. Wang, J. Li, X. Wang, M. Ma, M. Wang, 4D printing of highly printable and shape morphing hydrogels composed of alginate and methylcellulose, Materials & Design 205 (2021) 109699.

[138] Y.S. Lui, W.T. Sow, L.P. Tan, Y. Wu, Y. Lai, H. Li, 4D printing and stimuli-responsive materials in biomedical aspects, Acta Biomaterialia 92 (2019) 19-36.

[139] S. Ghosh, S. Chaudhuri, P. Roy, D. Lahiri, 4D Printing in Biomedical Engineering: a State-of-the-Art Review of Technologies, Biomaterials, and Application, Regenerative Engineering and Translational Medicine (2022) 1-27.

[140] S. Lanzalaco, P. Turon, C. Weis, C. Mata, E. Planas, C. Alemán, E. Armelin, Toward the New Generation of Surgical Meshes with 4D Response: Soft, Dynamic, and Adaptable, Advanced Functional Materials 30(36) (2020) 2004145-2004145.

[141] J.A. Ormiston, P.W. Serruys, E. Regar, D. Dudek, L. Thuesen, M.W. Webster, Y. Onuma, H.M. Garcia-Garcia, R. McGreevy, S. Veldhof, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, Lancet (London, England) 371(9616) (2008) 899-907.

[142] Y. Onuma, D. Dudek, L. Thuesen, M. Webster, K. Nieman, H.M. Garcia-Garcia, J.A. Ormiston, P.W. Serruys, Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimuseluting scaffold in patients with de novo coronary artery disease: The absorb cohort a trial, JACC: Cardiovascular Interventions 6(10) (2013) 999-1009.

[143] B. Morena, S. Alberto, F. Luca Andrea, G. Francesco, C. Marco, Mesh Fixation Methods in Groin Hernia Surgery, in: G. Angelo (Ed.), Techniques and Innovation in Hernia Surgery, IntechOpen, Rijeka, 2019, p. Ch. 7.

[144] M. MacEwan, L. Jeng, T. Kovács, E. Sallade, Clinical Application of Bioresorbable, Synthetic, Electrospun Matrix in Wound Healing, Bioengineering (Basel) 10(1) (2022).

[145] C.J. Martini, B. Burgess, J.H. Ghodasra, Treatment of traumatic crush injury using a synthetic hybrid-scale fiber matrix in conjunction with split-thickness skin graft, Foot & Ankle Surgery: Techniques, Reports & Cases 2(1) (2022) 100112.

[146] B.P. Abicht, G.A. Deitrick, M.R. MacEwan, L. Jeng, Evaluation of wound healing of diabetic foot ulcers in a prospective clinical trial using a synthetic hybrid-scale fiber matrix, Foot & Ankle Surgery: Techniques, Reports & Cases 2(1) (2022) 100135.

[147] E.C. Barton, B.P. Abicht, Lower extremity wounds treated with a synthetic hybrid-scale fiber matrix, Foot & Ankle Surgery: Techniques, Reports & Cases 1(3) (2021) 100076.

[148] M.J. Regulski, M.R. MacEwan, Implantable Nanomedical Scaffold Facilitates Healing of Chronic Lower Extremity Wounds, Wounds 30(8) (2018) E77-E80.

[149] J. McGowan, Reconstruction of post-Mohs surgical wounds using a novel nanofiber matrix, Wounds 34(8) (2022) 209-215.

[150] E.W. Temple, Treatment of Hematomas Using a Synthetic Hybrid-Scale Fiber Matrix, Cureus 14(7) (2022) e26491.

[151] K. Herron, Treatment of a Complex Pressure Ulcer Using a Synthetic Hybrid-Scale Fiber Matrix, Cureus 13(4) (2021) e14515.

[152] M. Vallery, T. Shannon, Augmented flap reconstruction of complex pressure ulcers using synthetic hybrid-scale fiber matrix, Wounds 33(1) (2022) 1-10.

[153] M. Ri, M. Ohashi, R. Makuuchi, M. Hayami, T. Sano, S. Nunobe, Clinical Impact of Polyglycolic Acid Mesh to Reduce Pancreas-Related Complications After Minimally Invasive Surgery for Gastric Cancer: A Propensity Score Matching Analysis, Journal of gastric cancer 24(2) (2024) 220-230.

[154] Q. Hu, R. Zhang, H. Zhang, D. Yang, S. Liu, Z. Song, Y. Gu, M. Ramalingam, Topological Structure Design and Fabrication of Biocompatible PLA/TPU/ADM Mesh with Appropriate Elasticity for Hernia Repair, Macromolecular bioscience 21(6) (2021) e2000423.

[155] N. Ovcharenko, H. Greenwell, D. Katwal, A. Patel, M. Hill, B. Shumway, B.L.

Cockerham, 3rd, A Comparison of the Effect of Barrier Membranes on Clinical and Histologic Hard and Soft Tissue Healing with Ridge Preservation, The International journal of periodontics & restorative dentistry 40(3) (2020) 365-371.

[156] S.Y. Turin, K. Gutowski, Bioabsorbable Polydioxanone Mesh for Soft Tissue Reinforcement in Revisional Breast Surgery, Aesthetic Surgery Journal Open Forum 4 (2022).
[157] Y.J. Park, J.H. Cha, S.I. Bang, S.Y. Kim, Clinical Application of Three-Dimensionally Printed Biomaterial Polycaprolactone (PCL) in Augmentation Rhinoplasty, Aesthetic Plastic Surgery 43(2) (2019) 437-446.

[158] Y. Renard, L. de Mestier, J. Henriques, P. de Boissieu, P. de Mestier, A. Fingerhut, J.P. Palot, R. Kianmanesh, Absorbable Polyglactin vs. Non-Cross-linked Porcine Biological Mesh for the Surgical Treatment of Infected Incisional Hernia, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 24(2) (2020) 435-443.

[159] P. Priego Jiménez, J.L. Salvador Sanchís, V. Ángel, J. Escrig-Sos, Short-term results for laparoscopic repair of large paraesophageal hiatal hernias with Gore Bio A® mesh, International Journal of Surgery 12(8) (2014) 794-797.

[160] M.J. Rosen, J.J. Bauer, M. Harmaty, A.M. Carbonell, W.S. Cobb, B. Matthews, M.I. Goldblatt, D.J. Selzer, B.K. Poulose, B.M.E. Hansson, C. Rosman, J.J. Chao, G.R. Jacobsen, Multicenter, prospective, longitudinal study of the recurrence, surgical site infection, and quality of life after contaminated ventral hernia repair using biosynthetic absorbable mesh: The COBRA study, Annals of Surgery 265(1) (2017) 205-211.

[161] J.S. Roth, G.J. Anthone, D.J. Selzer, B.K. Poulose, J.G. Bittner, W.W. Hope, R.M. Dunn, R.G. Martindale, M.I. Goldblatt, D.B. Earle, J.R. Romanelli, G.J. Mancini, J.A. Greenberg, J.G. Linn, E. Parra-Davila, B.J. Sandler, C.R. Deeken, G.R. Voeller, Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-up, Surgical Endoscopy 32(4) (2018) 1929-1936.

[162] L.M. Van den Dop, M.M.J. Van Rooijen, T. Tollens, L.N. Jørgensen, T.S. De Vries-Reilingh, G. Piessen, F. Köckerling, M. Miserez, M. Dean, F. Berrevoet, B. Dousset, H.L. Van Westreenen, F. Gossetti, G.W.M. Tetteroo, A. Koch, M.F. Boomsma, J.F. Lange, J. Jeekel, Five-Year Follow-Up of a Slowly Resorbable Biosynthetic P4HB Mesh (Phasix) in VHWG Grade 3 Incisional Hernia Repair, Annals of surgery open : perspectives of surgical history, education, and clinical approaches 4(4) (2023) e366.

[163] M.A.J. Sawyer, New Ovine Polymer-Reinforced Bioscaffold in Hiatal Hernia Repair, Jsls-Journal of the Society of Laparoendoscopic Surgeons 22(4) (2018).

[164] A.G. Barranquero, R. Villalobos Mori, Y. Maestre González, G.P. Protti, G. López Soler, F. Villarreal León, I.J. González Alfaro, J.J. Olsina Kissler, Parietex<sup>™</sup> Composite Ventral Patch for primary and incisional hernia repair, ANZ journal of surgery (2023).

[165] X. Briennon, E. Lermite, K. Meunier, E. Desbois, A. Hamy, J.P. Arnaud, Surgical treatment of large incisional hernias by intraperitoneal insertion of Parietex® composite mesh with an associated aponeurotic graft (280 cases), Journal of visceral surgery 148(1) (2011) 54-58.

[166] A.J. Rios-Diaz, M. Hitchner, A.N. Christopher, R. Broach, J.R. Cunning, J.P. Fischer, Early Clinical and Patient-Reported Outcomes of a New Hybrid Mesh for Incisional Hernia Repair, Journal of Surgical Research 265 (2021) 49-59.

[167] D.W. Grantham, C.R. Doerhoff, J.G. Linn, E.J. Mallico, R.G. Washington, Jr., Evaluation of Long-term Performance of the GORE SYNECOR Intraperitoneal Biomaterial in the Treatment of Inguinal Hernias, Surgical laparoscopy, endoscopy & percutaneous techniques 33(3) (2023) 231-234.

[168] L. Mettler, J. Hucke, B. Bojahr, H.R. Tinneberg, N. Leyland, R. Avelar, A safety and efficacy study of a resorbable hydrogel for reduction of post-operative adhesions following myomectomy, Human reproduction (Oxford, England) 23(5) (2008) 1093-100.

[169] C.E. Hart, A. Loewen-Rodriguez, J. Lessem, Dermagraft: Use in the Treatment of Chronic Wounds, Advances in wound care 1(3) (2012) 138-141.

[170] K. Harding, M. Sumner, M. Cardinal, A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers, International wound journal 10(2) (2013) 132-7.

[171] B. Allan, R. Ruan, E. Landao-Bassonga, N. Gillman, T. Wang, J. Gao, Y. Ruan, Y. Xu, C. Lee, M. Goonewardene, Collagen membrane for guided bone regeneration in dental and orthopedic applications, Tissue Engineering Part A 27(5-6) (2021) 372-381.

[172] T. Kanno, S. Sukegawa, Y. Furuki, Y. Nariai, J. Sekine, Overview of innovative advances in bioresorbable plate systems for oral and maxillofacial surgery, Japanese Dental Science Review 54(3) (2018) 127-138.

[173] S. Sukegawa, T. Kanno, K. Matsumoto, Y. Sukegawa-Takahashi, M. Masui, Y. Furuki, Complications of a poly-l-lactic acid and polyglycolic acid osteosynthesis device for internal fixation in maxillofacial surgery, Odontology 106(4) (2018) 360-368.

[174] B. Pandya, T. Huda, D. Gupta, B. Mehra, R. Narang, Abdominal Wall Hernias: An Epidemiological Profile and Surgical Experience from a Rural Medical College in Central India, Surgery journal (New York, N.Y.) 7(1) (2021) e41-e46.

[175] J.W.A. Burger, R.W. Luijendijk, W.C.J. Hop, J.A. Halm, E.G.G. Verdaasdonk, J. Jeekel, Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia, Annals of surgery 240(4) (2004) 578.

[176] A.S. Timmer, J.J. Claessen, I.M. Brouwer de Koning, S.M. Haenen, E.J. Belt, A.J. Bastiaansen, E.G. Verdaasdonk, C.P. Wolffenbuttel, W.H. Schreurs, W.A. Draaisma, Clinical outcomes of open abdominal wall reconstruction with the use of a polypropylene reinforced tissue matrix: a multicenter retrospective study, Hernia 26(5) (2022) 1241-1250.

[177] E. Asti, A. Lovece, L. Bonavina, P. Milito, A. Sironi, G. Bonitta, S. Siboni, Laparoscopic management of large hiatus hernia. five-year cohort study and comparison of mesh-augmented versus standard crura repair, Surgical endoscopy 30(12) (2016) 5404-5409.

[178] H. Konstantinidis, C. Charisis, Surgical treatment of large and complicated hiatal hernias with the new resorbable mesh with hydrogel barrier (Phasix<sup>TM</sup> ST): a preliminary study, Journal of Robotic Surgery 17(1) (2023) 141-146.

[179] C.R. Deeken, B.D. Matthews, Characterization of the mechanical strength, resorption properties, and histologic characteristics of a fully absorbable material (Poly-4-

hydroxybutyrate—PHASIX Mesh) in a porcine model of hernia repair, International Scholarly Research Notices 2013 (2013).

[180] C.R. Deeken, D.H. Gagne, A. Badhwar, Mechanical and histological characteristics of phasix<sup>™</sup> ST mesh in a porcine model of hernia repair, Journal of Investigative Surgery 35(2) (2022) 415-423.

[181] E. Vauclair, M. Bert, O. Facy, N. Cheynel, P. Rat, P. Ortega-Deballon, What results can be expected one year after complex incisional hernia repair with biosynthetic mesh?, Journal of visceral surgery 158(2) (2021) 111-117.

[182] F. García-Moreno, P. Pérez-López, S. Sotomayor, B. Pérez-Köhler, Y. Bayon, G. Pascual, J.M. Bellón, Comparing the host tissue response and peritoneal behavior of composite meshes used for ventral hernia repair, journal of surgical research 193(1) (2015) 470-482.

[183] D.P. Martin, A. Badhwar, D.V. Shah, S. Rizk, S.N. Eldridge, D.H. Gagne, A. Ganatra, R.E. Darois, S.F. Williams, H.C. Tai, J.R. Scott, Characterization of poly-4-hydroxybutyrate mesh for hernia repair applications, Journal of Surgical Research 184(2) (2013) 766-773.

[184] C. Pineda Molina, G.S. Hussey, A. Liu, J. Eriksson, W.A. D'Angelo, S.F. Badylak, Role of 4-hydroxybutyrate in increased resistance to surgical site infections associated with surgical meshes, Biomaterials 267 (2021) 120493.

[185] J.S. Roth, G.J. Anthone, D.J. Selzer, B.K. Poulose, J.G. Bittner, W.W. Hope, R.M. Dunn, R.G. Martindale, M.I. Goldblatt, D.B. Earle, J.R. Romanelli, G.J. Mancini, J.A. Greenberg, J.G. Linn, E. Parra-Davila, B.J. Sandler, C.R. Deeken, G.R. Voeller, Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-up, Surg Endosc 32(4) (2018) 1929-1936.

[186] L. Fair, M. Ward, P. Adhikari, D. Tran, E. Pina, S. Ramakrishnan, G. Ogola, B. Aladegbami, S. Leeds, Coated poly-4-hydroxybutyrate (Phasix ST) mesh is safe and effective for hiatal hernia repair: our institutional experience and review of the literature, Surg Endosc 38(2) (2024) 830-836.

[187] B. Clapp, A.M. Kara, P.J. Nguyen-Lee, H.M. Annabi, L. Alvarado, J.D. Marr, O.M. Ghanem, B. Davis, Does bioabsorbable mesh reduce hiatal hernia recurrence rates? A metaanalysis, Surg Endosc 37(3) (2023) 2295-2303.

[188] C.R. Deeken, M.J. Rosen, B.K. Poulose, K. Bradbury, L.C. Huang, J. Ma, A. Badhwar, Early wound morbidity and clinical outcomes associated with P4HB mesh compared to permanent synthetic mesh in umbilical and small to medium, routine ventral hernia repairs, Front Surg 10 (2023) 1280991.

[189] L.M. Van den Dop, M.M.J. Van Rooijen, T. Tollens, L.N. Jorgensen, T.S. De Vries-Reilingh, G. Piessen, F. Kockerling, M. Miserez, M. Dean, F. Berrevoet, B. Dousset, H.L. Van Westreenen, F. Gossetti, G.W.M. Tetteroo, A. Koch, M.F. Boomsma, J.F. Lange, J. Jeekel, Five-Year Follow-Up of a Slowly Resorbable Biosynthetic P4HB Mesh (Phasix) in VHWG Grade 3 Incisional Hernia Repair, Ann Surg Open 4(4) (2023) e366.

[190] M.A. Plymale, D.L. Davenport, A. Dugan, A. Zachem, J.S. Roth, Ventral hernia repair with poly-4-hydroxybutyrate mesh, Surgical Endoscopy 32(4) (2018) 1689-1694.

[191] S.P. Zhong, Y.Z. Zhang, C.T. Lim, Tissue scaffolds for skin wound healing and dermal reconstruction, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2(5) (2010) 510-525.

[192] Z.-L. Farmer, J. Domínguez-Robles, C. Mancinelli, E. Larrañeta, D.A. Lamprou, Urogynecological surgical mesh implants: New trends in materials, manufacturing and therapeutic approaches, International Journal of Pharmaceutics 585 (2020) 119512.

[193] N. Mangir, S. Roman, C.R. Chapple, S. MacNeil, Complications related to use of mesh implants in surgical treatment of stress urinary incontinence and pelvic organ prolapse: infection or inflammation?, World Journal of Urology 38 (2020) 73-80.

[194] U.S.F.a.D. Administration, Urogynecologic Surgical Mesh Implants 2019. https://www.fda.gov/medical-devices/implants-and-prosthetics/urogynecologic-surgical-meshimplants. (Accessed 28/11/2023.

[195] T.G. Administration, Urogynaecological (transvaginal) surgical mesh hub, 2017. https://www.tga.gov.au/products/medical-devices/urogynaecological-transvaginal-surgical-mesh-hub. (Accessed 28/11/2023.

[196] S. Gruber-Blum, R.H. Fortelny, C. Keibl, J. Brand, M. Lechner, H. Redl, A.H. Petter-Puchner, Liquid antiadhesive agents for intraperitoneal hernia repair procedures: Artiss®

compared to CoSeal® and Adept® in an IPOM rat model, Surgical Endoscopy 31(12) (2017) 4973-4980.

[197] G. Callewaert, S. Housmans, L. Cattani, S. Pacquée, A. D'Hoore, J. Wyndaele, F. Van der Aa, J. Deprest, Medium-term outcome of laparoscopic sacrocolpopexy using polivinylidene fluoride as compared to a hybrid polyglecaprone and polypropylene mesh: A matched control study, Neurourology and urodynamics 38(7) (2019) 1874-1882.

[198] V.F. Coindre, Y. Hu, M.V. Sefton, Poly-Methacrylic Acid Cross-Linked with Collagen Accelerates Diabetic Wound Closure, ACS biomaterials science & engineering 6(11) (2020) 6368-6377.

[199] M. Mir, M.N. Ali, A. Barakullah, A. Gulzar, M. Arshad, S. Fatima, M. Asad, Synthetic polymeric biomaterials for wound healing: a review, Progress in biomaterials 7(1) (2018) 1-21.
[200] E. Hewitt, S. Mros, M. McConnell, J.D. Cabral, A. Ali, Melt-electrowriting with novel milk protein/PCL biomaterials for skin regeneration, Biomedical materials (Bristol, England) 14(5) (2019) 055013.

[201] G. Nicoletti, F. Brenta, M. Bleve, T. Pellegatta, A. Malovini, A. Faga, P. Perugini, Longterm in vivo assessment of bioengineered skin substitutes: a clinical study, Journal of tissue engineering and regenerative medicine 9(4) (2015) 460-8.

[202] H.C. Korting, C. Schöllmann, R.J. White, Management of minor acute cutaneous wounds: importance of wound healing in a moist environment, J Eur Acad Dermatol Venereol 25(2) (2011) 130-7.

[203] N.K. Soldatos, P. Stylianou, V.P. Koidou, N. Angelov, R. Yukna, G.E. Romanos, Limitations and options using resorbable versus nonresorbable membranes for successful guided bone regeneration, Quintessence International 48(2) (2017) 131-147.

[204] P. Aprile, D. Letourneur, T. Simon-Yarza, Membranes for Guided Bone Regeneration: A Road from Bench to Bedside, 9(19) (2020) 2000707.

[205] C.H. Hämmerle, R.E. Jung, Bone augmentation by means of barrier membranes, Periodontology 2000 33 (2003) 36-53.

[206] Implantable bicomponent fibres, Medical Textiles (MARCH) (2004) 12.

[207] I.A. Rodriguez, G.S. Selders, A.E. Fetz, C.J. Gehrmann, S.H. Stein, J.A. Evensky, M.S. Green, G.L. Bowlin, Barrier membranes for dental applications: A review and sweet advancement in membrane developments, Mouth Teeth 2(1) (2018) 1-9.

[208] R.E. Jung, N. Fenner, C.H. Hämmerle, N.U. Zitzmann, Long-term outcome of implants placed with guided bone regeneration (GBR) using resorbable and non-resorbable membranes after 12-14 years, Clinical oral implants research 24(10) (2013) 1065-73.

[209] S. Sudarsan, K.V. Arun, M.S. Priya, R. Arun, Clinical and histological evaluation of alloderm GBR and BioOss in the treatment of Siebert's class I ridge deficiency, Journal of Indian Society of Periodontology 12(3) (2008) 73.

[210] S. Arunjaroensuk, S. Panmekiate, A. Pimkhaokham, The Stability of Augmented Bone Between Two Different Membranes Used for Guided Bone Regeneration Simultaneous with Dental Implant Placement in the Esthetic Zone, The International journal of oral & maxillofacial implants 33(1) (2018) 206-216.

[211] J. Hartlev, R. Spin-Neto, S. Schou, F. Isidor, S.E. Nørholt, Cone beam computed tomography evaluation of staged lateral ridge augmentation using platelet-rich fibrin or resorbable collagen membranes in a randomized controlled clinical trial, Clinical oral implants research 30(3) (2019) 277-284.

[212] C. Vaquette, J. Mitchell, T. Fernandez-Medina, S. Kumar, S. Ivanovski, Resorbable additively manufactured scaffold imparts dimensional stability to extraskeletally regenerated bone, Biomaterials 269 (2021) 120671.

[213] S.A. Faraj, A. Kutkut, R.C. Taylor, A. Villasante-Tezanos, S.S. Huja, D.R. Dawson, N. Almehmadi, M. Al-Sabbagh, Comparison of Dehydrated Human Amnion-Chorion and Type 1 Bovine Collagen Membranes in Alveolar Ridge Preservation: A Clinical and Histological Study, The Journal of oral implantology 47(5) (2021) 385-393.

[214] M.A. Carro, G. Donofrio, E. Tokgöz, Surgical Reconstruction of Craniofacial Malformations, in: E. Tokgöz, M.A. Carro (Eds.), Cosmetic and Reconstructive Facial Plastic Surgery: A Review of Medical and Biomedical Engineering and Science Concepts, Springer Nature Switzerland, Cham, 2023, pp. 151-179.

[215] M. Peled, D. Aizenbud, J. Horwitz, E.E. Machtei, Treatment of osseous cleft palate defects: a preliminary evaluation of novel treatment modalities, The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association 42(4) (2005) 344-8.

[216] S. Sukegawa, T. Kanno, N. Katase, A. Shibata, Y. Takahashi, Y. Furuki, Clinical Evaluation of an Unsintered Hydroxyapatite/Poly-L-Lactide Osteoconductive Composite Device for the Internal Fixation of Maxillofacial Fractures, The Journal of craniofacial surgery 27(6) (2016) 1391-7.

[217] Y. Matsuda, M. Karino, T. Okui, T. Kanno, Complications of Poly-I-Lactic Acid and Polyglycolic Acid (PLLA/PGA) Osteosynthesis Systems for Maxillofacial Surgery: A Retrospective Clinical Investigation, 13(6) (2021) 889.

[218] M.C. DurmuŞlar, C. Alpaslan, G. Alpaslan, M. Çakır, Clinical and radiographic evaluation of the efficacy of platelet-rich plasma combined with hydroxyapatite bone graft substitutes in the treatment of intra-bony defects in maxillofacial region, Acta Odontologica Scandinavica 72(8) (2014) 948-953.

[219] E.A. Schulten, H.J. Prins, J.R. Overman, M.N. Helder, C.M. ten Bruggenkate, J. Klein-Nulend, A novel approach revealing the effect of a collagenous membrane on osteoconduction in maxillary sinus floor elevation with  $\beta$ -tricalcium phosphate, European cells & materials 25 (2013) 215-28.

[220] S. Li, J. Zhao, Y. Xie, T. Tian, T. Zhang, X. Cai, Hard tissue stability after guided bone regeneration: a comparison between digital titanium mesh and resorbable membrane, International Journal of Oral Science 13(1) (2021) 37.

[221] G. Cossellu, G. Farronato, D. Farronato, G. Ceschel, F. Angiero, Space-maintaining management in maxillary sinus lifting: a novel technique using a resorbable polymeric thermoreversible gel, International journal of oral and maxillofacial surgery 46(5) (2017) 648-654.
[222] W.P. Adams, Jr., D.M. Toriumi, B.W. Van Natta, Clinical Use of GalaFLEX in Facial and Breast Cosmetic Plastic Surgery, Aesthetic surgery journal 36(suppl 2) (2016) S23-s32.

[223] M. Aberg, C. Ljungberg, E. Edin, H. Millqvist, E. Nordh, A. Theorin, G. Terenghi, M. Wiberg, Clinical evaluation of a resorbable wrap-around implant as an alternative to nerve repair: A prospective, assessor-blinded, randomised clinical study of sensory, motor and functional recovery after peripheral nerve repair, Journal of Plastic Reconstructive and Aesthetic Surgery 62(11) (2009) 1503-1509.

[224] M.F. Meek, J.H. Coert, Recovery of two-point discrimination function after digital nerve repair in the hand using resorbable FDA- and CE-approved nerve conduits, Journal of Plastic, Reconstructive and Aesthetic Surgery 66(10) (2013) 1307-1315.

[225] P. Chen, A. Wang, W. Haynes, E. Landao-Bassonga, C. Lee, R. Ruan, W. Breidahl, B. Shiroud Heidari, C.A. Mitchell, M. Zheng, A bio-inductive collagen scaffold that supports human primary tendon-derived cell growth for rotator cuff repair, Journal of Orthopaedic Translation 31 (2021) 91-101.

himalpread

# **Graphical Abstract**

